{
  "meta": {
    "title": "35_Myocardial_Infarction_Drugs_For_Heart_Failure",
    "url": "https://brainandscalpel.vercel.app/35-myocardial-infarction-drugs-for-heart-failure-bd687983.html",
    "scrapedAt": "2025-11-30T06:59:55.247Z"
  },
  "questions": [
    {
      "id": 51424,
      "choices": [
        {
          "id": 290699,
          "text": "Deceased appetite"
        },
        {
          "id": 290700,
          "text": "Increased cardiac contractility"
        },
        {
          "id": 290701,
          "text": "Tachycardia"
        },
        {
          "id": 290702,
          "text": "Increased PR interval on the ECG"
        }
      ],
      "text": "A patient Vipin has been taking digoxin for several years and is about to receive atropine for other indication. A common side effect of digoxin that can be blocked by atropine is",
      "unique_key": "Q1853394",
      "question_audio": null,
      "question_video": null,
      "map_id": 34261690,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Increased PR interval on the ECG. Digoxin is a cardiac glycoside that enhances vagal tone, leading to increased parasympathetic activity, which slows conduction through the atrioventricular (AV) node. This effect is reflected on an ECG as a prolonged PR interval. Atropine, an anticholinergic agent, blocks muscarinic receptors and inhibits vagal influences on the heart, thereby counteracting the AV nodal suppression caused by digoxin. By doing so, atropine can reduce or prevent the PR interval prolongation seen with digoxin therapy. Incorrect Options: (A) Decreased appetite: Digoxin can cause gastrointestinal side effects, including nausea, vomiting, and anorexia (loss of appetite). However, these effects are due to central and peripheral mechanisms involving the chemoreceptor trigger zone and direct gastric irritation. Atropine does not directly counteract these effects, making this answer incorrect. (B) Increased cardiac contractility: Digoxin exerts a positive inotropic effect by inhibiting the Na+/K+-ATPase pump, leading to increased intracellular calcium and enhanced myocardial contractility. Atropine does not influence this mechanism, so it does not counteract the positive inotropic effect of digoxin. (C) Tachycardia: Digoxin typically slows heart rate due to its vagotonic effects. While atropine can increase heart rate by blocking vagal influence, it does not directly counteract tachycardia since digoxin itself does not cause this effect. Instead, digoxin overdose can lead to bradycardia or AV block, conditions where atropine may be useful.",
      "correct_choice_id": 290702,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/37503391698477911/37503391698477911.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/37503391698477911/37503391698477911.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51425,
      "choices": [
        {
          "id": 290703,
          "text": "Digibind"
        },
        {
          "id": 290704,
          "text": "Lignocaine"
        },
        {
          "id": 290705,
          "text": "Potassium"
        },
        {
          "id": 290706,
          "text": "None of these"
        }
      ],
      "text": "Which of the following is not given in acute severe digitalis toxicity?",
      "unique_key": "Q4135134",
      "question_audio": null,
      "question_video": null,
      "map_id": 34390842,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Potassium. In acute severe digitalis (digoxin) toxicity, administration of potassium is generally avoided unless the patient is hypokalemic. Digoxin toxicity often leads to hyperkalemia due to Na?/K?-ATPase inhibition, causing potassium to leak out of cells. Giving additional potassium in this setting can worsen hyperkalemia and increase the risk of fatal arrhythmias. Potassium supplementation is only indicated if hypokalemia is present, as low potassium levels increase digoxin binding to Na?/K?-ATPase, exacerbating toxicity. However, in acute toxicity with normal or high potassium levels, it is not routinely given. Explanation of Incorrect Options: (A) Digibind: Digibind (digoxin-specific antibody fragments, also called Digoxin Immune Fab) is the first-line treatment for life-threatening digoxin toxicity. It binds free digoxin, neutralizing its effects and promoting renal excretion. It is indicated in cases of severe toxicity, such as life-threatening arrhythmias or significant hyperkalemia. (B) Lignocaine: Lignocaine (lidocaine) is an antiarrhythmic drug used to treat ventricular arrhythmias associated with digoxin toxicity. It helps suppress ectopic ventricular activity without significantly affecting AV conduction, making it a safer option compared to other antiarrhythmics like amiodarone or quinidine, which may worsen toxicity. (D) None of these: Since potassium is not routinely given in acute severe digoxin toxicity, this option is incorrect because there is at least one option (potassium) that should be avoided in certain situations.",
      "correct_choice_id": 290705,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/20872631698477932/20872631698477932.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/20872631698477932/20872631698477932.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51426,
      "choices": [
        {
          "id": 290707,
          "text": "These should be started at very low dose and slowly titrated upwards"
        },
        {
          "id": 290708,
          "text": "Carvedilol is most widely used Beta blocker"
        },
        {
          "id": 290709,
          "text": "These can reduce mortality in CHF patients"
        },
        {
          "id": 290710,
          "text": "These are drug of choice in acute decompensated heart failure"
        }
      ],
      "text": "Which of the following is NOT true about the use of Beta blockers in CHF",
      "unique_key": "Q2208461",
      "question_audio": null,
      "question_video": null,
      "map_id": 34086184,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) These are drug of choice in acute decompensated heart failure. Beta-blockers are not used as first-line treatment in acute decompensated heart failure (ADHF) because they can worsen hemodynamic instability by reducing heart rate and myocardial contractility. In ADHF, the priority is to stabilize the patient with diuretics, vasodilators, and inotropic agents (if needed) to improve cardiac output and reduce congestion. Beta-blockers are typically continued in patients who were already on them if hemodynamics allow, but they should not be initiated during acute decompensation. Once the patient is stabilized, beta-blockers can be introduced gradually for long-term management. Explanation of Incorrect Options: (A) These should be started at very low dose and slowly titrated upwards: This is true. In chronic heart failure, beta-blockers are started at very low doses and gradually increased over weeks to months. This approach helps prevent sudden worsening of heart failure symptoms due to their negative inotropic effects. (B) Carvedilol is the most widely used beta-blocker: This is true. Among beta-blockers, carvedilol, bisoprolol, and metoprolol succinate have been shown to improve survival in chronic heart failure. Carvedilol, in particular, is preferred because it blocks both beta- and alpha-adrenergic receptors, providing additional vasodilatory benefits. (C) These can reduce mortality in CHF patients: This is true. Clinical trials such as the MERIT-HF, COPERNICUS, and CIBIS-II studies have demonstrated that beta-blockers significantly reduce mortality and hospitalizations in heart failure patients with reduced ejection fraction (HFrEF). They work by reducing sympathetic overactivation, lowering myocardial oxygen demand, and preventing disease progression.",
      "correct_choice_id": 290710,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/15825731698478031/15825731698478031.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/15825731698478031/15825731698478031.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51427,
      "choices": [
        {
          "id": 290711,
          "text": "It affords rapid symptomatic relief in CHF patients"
        },
        {
          "id": 290712,
          "text": "It should be administered in low doses to prevent hyperkalemia"
        },
        {
          "id": 290713,
          "text": "It affords prognostic benefit in severe heart failure over and above that afforded by ACE inhibitors"
        },
        {
          "id": 290714,
          "text": "It helps to overcome the Refractoriness to thiazides"
        }
      ],
      "text": "All of the following statements about the use of spironolactone in CHF are true except",
      "unique_key": "Q1077292",
      "question_audio": null,
      "question_video": null,
      "map_id": 34317359,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) It affords rapid symptomatic relief in CHF patients. Spironolactone is a mineralocorticoid (aldosterone) receptor antagonist that provides long-term benefits in chronic heart failure (CHF) by reducing cardiac remodeling, fibrosis, and mortality. However, it does not provide rapid symptomatic relief in CHF patients. Unlike loop diuretics, which quickly reduce pulmonary congestion and edema, spironolactone has a slow onset of action and primarily serves as a potassium-sparing diuretic and an aldosterone antagonist, helping in the long-term management of heart failure rather than immediate symptom relief. Explanation of Incorrect Options: (B) It should be administered in low doses to prevent hyperkalemia: This is true. Spironolactone can cause hyperkalemia, especially in CHF patients who are already on ACE inhibitors or ARBs, which also increase potassium levels. Therefore, it should be started at low doses (e.g., 12.5–25 mg daily) and titrated cautiously while monitoring potassium and renal function. (C) It affords prognostic benefit in severe heart failure over and above that afforded by ACE inhibitors: This is true. The RALES (Randomized Aldactone Evaluation Study) showed that spironolactone significantly reduces mortality in severe heart failure (NYHA Class III-IV) when added to standard therapy, including ACE inhibitors. This is due to its role in blocking aldosterone-mediated cardiac remodeling and fibrosis, which ACE inhibitors alone cannot fully prevent. (D) It helps to overcome the refractoriness to thiazides: This is true. Thiazide diuretics can lead to hypokalemia and secondary hyperaldosteronism, which can reduce their effectiveness over time. Spironolactone, by blocking aldosterone, helps counteract this effect, making diuretics more effective in resistant cases of heart failure or hypertension.",
      "correct_choice_id": 290711,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/47412661698478072/47412661698478072.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/47412661698478072/47412661698478072.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51428,
      "choices": [
        {
          "id": 290715,
          "text": "Amrinone"
        },
        {
          "id": 290716,
          "text": "Amiloride"
        },
        {
          "id": 290717,
          "text": "Amiodarone"
        },
        {
          "id": 290718,
          "text": "Carvedilol"
        }
      ],
      "text": "Which of the following drugs is beneficial in a Refractory congestive heart failure by increasing cardiac contractility and decreasing preload and afterload?",
      "unique_key": "Q9725715",
      "question_audio": null,
      "question_video": null,
      "map_id": 34031178,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Amrinone. Amrinone (also known as inamrinone) is a phosphodiesterase-3 (PDE-3) inhibitor that increases cardiac contractility (positive inotropic effect) and decreases both preload and afterload by promoting vasodilation. It works by inhibiting PDE-3, leading to increased intracellular cyclic AMP (cAMP) levels, which enhances calcium availability in cardiac myocytes, improving myocardial contraction. Additionally, cAMP-mediated vasodilation reduces systemic vascular resistance (afterload) and venous return (preload), making amrinone beneficial in refractory congestive heart failure (CHF) when standard therapies (such as ACE inhibitors and beta-blockers) are ineffective. Explanation of Incorrect Options: (B) Amiloride: Amiloride is a potassium-sparing diuretic that works by blocking epithelial sodium channels (ENaC) in the distal tubule and collecting ducts. It helps reduce sodium retention and fluid overload but does not increase cardiac contractility or significantly reduce afterload. It is not used for inotropic support in refractory CHF, making this option incorrect. (C) Amiodarone: Amiodarone is a class III antiarrhythmic drug used to manage ventricular and atrial arrhythmias in CHF patients. While it may improve survival by preventing arrhythmias, it does not have a significant effect on cardiac contractility, preload, or afterload. Therefore, it is not the correct answer. (D) Carvedilol: Carvedilol is a non-selective beta-blocker with alpha-blocking properties that reduces afterload via vasodilation and improves long-term CHF outcomes by reducing sympathetic activation and cardiac remodeling. However, beta-blockers do not acutely increase cardiac contractility; in fact, they have a negative inotropic effect initially, making them unsuitable for acute management of refractory CHF.",
      "correct_choice_id": 290715,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/74881531698478090/74881531698478090.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/74881531698478090/74881531698478090.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51429,
      "choices": [
        {
          "id": 290719,
          "text": "Digoxin"
        },
        {
          "id": 290720,
          "text": "Ramipril"
        },
        {
          "id": 290721,
          "text": "Spironolactone"
        },
        {
          "id": 290722,
          "text": "Dobutamine"
        }
      ],
      "text": "All of the following drugs are useful for long-term treatment of congestive heart failure except.",
      "unique_key": "Q2114084",
      "question_audio": null,
      "question_video": null,
      "map_id": 34915531,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Dobutamine. Dobutamine is a beta-1 adrenergic agonist that provides a short-term increase in cardiac contractility (positive inotropic effect) by stimulating beta-1 receptors, leading to increased cyclic AMP and enhanced calcium influx in cardiac myocytes. It is primarily used for acute decompensated heart failure (ADHF) and cardiogenic shock, where immediate improvement in cardiac output is required. However, dobutamine is not suitable for long-term treatment of congestive heart failure (CHF) because prolonged use can lead to tachyphylaxis, increased myocardial oxygen demand, and higher mortality due to arrhythmias and worsening heart failure. Explanation of Incorrect Options: (A) Digoxin: Digoxin is a cardiac glycoside that provides a mild positive inotropic effect by inhibiting the Na+/K+-ATPase pump, leading to increased intracellular calcium. It also enhances vagal tone, slowing AV nodal conduction, which is beneficial in heart failure with atrial fibrillation. While it does not improve survival, it is useful in long-term management by reducing hospitalizations and symptoms in CHF patients. (B) Ramipril: Ramipril is an angiotensin-converting enzyme (ACE) inhibitor) that plays a crucial role in long-term CHF management by reducing afterload, preventing cardiac remodeling, and improving survival. ACE inhibitors are considered first-line therapy in CHF with reduced ejection fraction (HFrEF) and significantly decrease morbidity and mortality. (C) Spironolactone: Spironolactone is an aldosterone antagonist that reduces fluid retention, prevents cardiac fibrosis, and improves survival in CHF patients, particularly those with severe heart failure (NYHA Class III-IV). The RALES trial demonstrated a significant mortality benefit when spironolactone was added to standard CHF therapy.",
      "correct_choice_id": 290722,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/19217031698478106/19217031698478106.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/19217031698478106/19217031698478106.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51430,
      "choices": [
        {
          "id": 290723,
          "text": "Decrease in mortality associated with CHF"
        },
        {
          "id": 290724,
          "text": "Prevention of pathological remodelling of ventricular myocardium"
        },
        {
          "id": 290725,
          "text": "Prevention of dangerous cardiac arrhythmias"
        },
        {
          "id": 290726,
          "text": "Antagonism of vasoconstriction due to sympathetic over activity"
        }
      ],
      "text": "All of the following are the actions of Beta-adrenoceptor blockers in CHF except",
      "unique_key": "Q6975221",
      "question_audio": null,
      "question_video": null,
      "map_id": 34982374,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Antagonism of vasoconstriction due to sympathetic overactivity. Beta-adrenoceptor blockers (beta-blockers) are a cornerstone in the long-term management of congestive heart failure (CHF) due to their ability to reduce mortality, prevent cardiac remodeling, and protect against arrhythmias. However, they do not directly antagonize vasoconstriction caused by sympathetic overactivity. While some beta-blockers (e.g., carvedilol) have additional alpha-blocking properties that promote vasodilation, most beta-blockers do not counteract vasoconstriction directly. Instead, they reduce sympathetic drive over time, leading to indirect benefits. In contrast, ACE inhibitors and ARBs are the primary agents used to counteract vasoconstriction in CHF. Explanation of Incorrect Options: (A) Decrease in mortality associated with CHF: This is true. Large clinical trials, such as MERIT-HF, CIBIS-II, and COPERNICUS, have shown that beta-blockers significantly reduce mortality in CHF patients. They achieve this by reducing myocardial oxygen demand, preventing arrhythmias, and counteracting neurohormonal activation, which contributes to heart failure progression. (B) Prevention of pathological remodeling of ventricular myocardium: This is true. CHF leads to ventricular remodeling, where the myocardium undergoes hypertrophy, fibrosis, and dilation in response to chronic stress. Beta-blockers inhibit the effects of catecholamines (e.g., norepinephrine), which drive these changes, thus preventing or even reversing remodeling over time. This leads to improved ventricular function and long-term prognosis. (C) Prevention of dangerous cardiac arrhythmias: This is true. Beta-blockers reduce the risk of ventricular tachycardia and fibrillation, which are common causes of sudden cardiac death in CHF patients. By slowing AV nodal conduction, decreasing ectopic activity, and reducing sympathetic stimulation, beta-blockers help stabilize the cardiac electrical system, lowering the risk of life-threatening arrhythmias.",
      "correct_choice_id": 290726,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/56837281698478126/56837281698478126.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/56837281698478126/56837281698478126.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51431,
      "choices": [
        {
          "id": 290727,
          "text": "Hypertension"
        },
        {
          "id": 290728,
          "text": "Atrial fibrillation"
        },
        {
          "id": 290729,
          "text": "Hypertrophic obstructive cardiomyopathy"
        },
        {
          "id": 290730,
          "text": "Mitral stenosis"
        }
      ],
      "text": "Digitalis is used in the treatment of acute CHF. It can also be used as a long-term maintenance therapy if CHF is associated with",
      "unique_key": "Q5179003",
      "question_audio": null,
      "question_video": null,
      "map_id": 34423944,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Atrial fibrillation. Digoxin is used as a long-term maintenance therapy in congestive heart failure (CHF) associated with atrial fibrillation (AF) due to its dual positive inotropic and negative chronotropic effects. It inhibits the Na+/K+-ATPase pump, leading to increased intracellular calcium and enhanced myocardial contractility, which helps in CHF. Additionally, digoxin increases vagal tone, slowing conduction through the atrioventricular (AV) node, thereby reducing the ventricular rate in atrial fibrillation. This rate control is crucial in CHF patients with rapid ventricular response (RVR) in AF, improving their symptoms and cardiac function. Incorrect Options: (A) Hypertension: This is incorrect because digoxin does not significantly lower blood pressure and is not a first-line drug for hypertension-related CHF. ACE inhibitors, ARBs, beta-blockers, and diuretics are preferred in CHF with hypertension because they address the underlying pathophysiology, including afterload reduction and neurohormonal modulation. (C) Hypertrophic obstructive cardiomyopathy (HOCM): This is incorrect because digoxin is contraindicated in HOCM. In HOCM, there is left ventricular outflow tract (LVOT) obstruction due to septal hypertrophy. Since digoxin increases contractility, it can worsen the obstruction, leading to increased symptoms and hemodynamic instability. Instead, beta-blockers or calcium channel blockers (e.g., verapamil) are preferred as they reduce myocardial contractility and improve diastolic filling. (D) Mitral stenosis: This is incorrect because digoxin has no direct role in mitral stenosis unless atrial fibrillation is also present. In mitral stenosis, left atrial enlargement and elevated left atrial pressure lead to pulmonary congestion and heart failure symptoms, but digoxin does not relieve valvular obstruction. If the patient develops AF with rapid ventricular response, digoxin may be used to control the ventricular rate, but it is not a primary treatment for mitral stenosis itself.",
      "correct_choice_id": 290728,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/44994941698478142/44994941698478142.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/44994941698478142/44994941698478142.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51432,
      "choices": [
        {
          "id": 290731,
          "text": "It reverses the pathological changes of CHF"
        },
        {
          "id": 290732,
          "text": "It prolongs the survival of CHF patient"
        },
        {
          "id": 290733,
          "text": "It is used to provide relief of symptoms"
        },
        {
          "id": 290734,
          "text": "All of these"
        }
      ],
      "text": "Advantage of using digoxin in CHF is",
      "unique_key": "Q1211244",
      "question_audio": null,
      "question_video": null,
      "map_id": 34762741,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) It is used to provide relief of symptoms. Digoxin is primarily used in congestive heart failure (CHF) for symptomatic relief, particularly in patients with reduced ejection fraction (HFrEF) and atrial fibrillation. It enhances myocardial contractility (positive inotropic effect) by inhibiting Na+/K+-ATPase, increasing intracellular calcium and improving cardiac output. Additionally, it reduces symptoms such as dyspnea and fatigue, helping to improve exercise tolerance. However, while digoxin reduces hospitalizations in CHF patients, it does not prolong survival or reverse disease pathology. Incorrect Options: (A) It reverses the pathological changes of CHF: This is incorrect because digoxin does not reverse ventricular remodeling or the progressive myocardial changes seen in CHF. Drugs like ACE inhibitors, ARBs, beta-blockers, and aldosterone antagonists are known to prevent or reverse pathological cardiac remodeling by reducing neurohormonal activation. Digoxin, in contrast, primarily improves symptoms without modifying disease progression. (B) It prolongs the survival of CHF patients: This is incorrect because studies, such as the DIG (Digitalis Investigation Group) trial, have shown that digoxin does not reduce mortality in CHF. Unlike beta-blockers, ACE inhibitors, and spironolactone, which have been proven to increase survival, digoxin's main benefit is symptomatic relief and reduction in hospitalizations, not prolongation of life. (D) All of these: This is incorrect because while digoxin provides symptomatic relief, it does not reverse CHF pathology or increase survival, making option (C) the correct choice.",
      "correct_choice_id": 290733,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/25221341698478161/25221341698478161.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/25221341698478161/25221341698478161.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51433,
      "choices": [
        {
          "id": 290735,
          "text": "Tubular secretion"
        },
        {
          "id": 290736,
          "text": "Hepatic metabolism"
        },
        {
          "id": 290737,
          "text": "Excretion in bile"
        },
        {
          "id": 290738,
          "text": "Glomerular filtration"
        }
      ],
      "text": "The most important channel of elimination of digoxin is",
      "unique_key": "Q2891827",
      "question_audio": null,
      "question_video": null,
      "map_id": 34239887,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Glomerular filtration. Digoxin is primarily eliminated by the kidneys through glomerular filtration. Around 70–80% of digoxin is excreted unchanged in the urine, with minimal metabolism in the liver. Since digoxin clearance is directly proportional to renal function, patients with renal impairment have reduced digoxin clearance, leading to drug accumulation and an increased risk of toxicity. Therefore, dose adjustments are necessary in patients with chronic kidney disease (CKD) or decreased glomerular filtration rate (GFR) to prevent toxicity. Explanation of Incorrect Options: (A) Tubular secretion: This is incorrect because while some drugs are eliminated through active tubular secretion, digoxin is primarily cleared by passive glomerular filtration. The role of tubular secretion in digoxin elimination is minor compared to glomerular filtration. Additionally, drugs like quinidine and verapamil can inhibit P-glycoprotein (P-gp) transporters in renal tubules, leading to reduced digoxin clearance and increased plasma levels. (B) Hepatic metabolism: This is incorrect because digoxin undergoes minimal hepatic metabolism. Unlike drugs that are extensively metabolized by the liver (e.g., beta-blockers, ACE inhibitors), digoxin is largely excreted unchanged by the kidneys. Hepatic metabolism plays a minor role in its elimination, making it less relevant in cases of liver dysfunction. (C) Excretion in bile: This is incorrect because biliary excretion accounts for only a small fraction of digoxin elimination. While some digoxin is excreted in bile and feces, this route is insignificant compared to renal excretion. Biliary clearance is more relevant for drugs like rifampin and statins, which undergo significant enterohepatic circulation.",
      "correct_choice_id": 290738,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51434,
      "choices": [
        {
          "id": 290739,
          "text": "Na+ K+ ATPase inhibitors"
        },
        {
          "id": 290740,
          "text": "Beta receptor agonists"
        },
        {
          "id": 290741,
          "text": "Alpha blockers"
        },
        {
          "id": 290742,
          "text": "Beta receptor antagonists"
        }
      ],
      "text": "Drugs that have been found to be useful in compensated heart failure include all of the following except.",
      "unique_key": "Q4775267",
      "question_audio": null,
      "question_video": null,
      "map_id": 34423181,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Beta receptor agonists. In compensated heart failure (CHF with stable hemodynamics), beta receptor agonists (such as dobutamine and dopamine) are not used because they provide only short-term benefits by increasing cardiac contractility (positive inotropic effect) but may lead to increased myocardial oxygen demand, arrhythmias, and desensitization of beta receptors with prolonged use. Beta agonists are primarily reserved for acute decompensated heart failure (ADHF), cardiogenic shock, or end-stage CHF when immediate hemodynamic support is required. Their long-term use has not been shown to improve survival and may even worsen outcomes due to increased myocardial stress and progression of heart failure. Incorrect Options: (A) Na+/K+ ATPase inhibitors (e.g., Digoxin): This is correct because digoxin is useful in compensated CHF, particularly in patients with atrial fibrillation. It inhibits the Na+/K+ ATPase pump, increasing intracellular calcium and enhancing cardiac contractility. This helps improve symptoms in heart failure with reduced ejection fraction (HFrEF), although it does not reduce mortality. (C) Alpha blockers: This is correct because alpha blockers (e.g., prazosin, carvedilol as a mixed alpha-beta blocker) can be used in CHF by causing vasodilation, reducing afterload, and improving cardiac output. However, pure alpha blockers alone are not first-line therapy and are less commonly used than ACE inhibitors or beta-blockers. Carvedilol, which has both alpha- and beta-blocking effects, is particularly beneficial in CHF by reducing vasoconstriction and sympathetic overactivity. (D) Beta receptor antagonists (Beta-blockers): This is correct because beta-blockers (e.g., carvedilol, bisoprolol, metoprolol succinate) are a mainstay of CHF treatment. They reduce sympathetic overactivation, prevent pathological cardiac remodeling, and improve survival in CHF patients. However, beta-blockers should be introduced at low doses and only in stable, compensated CHF because starting them in acute decompensated heart failure can worsen symptoms.",
      "correct_choice_id": 290740,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/71028231698478192/71028231698478192.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/71028231698478192/71028231698478192.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51435,
      "choices": [
        {
          "id": 290743,
          "text": "Amiodarone"
        },
        {
          "id": 290744,
          "text": "Quinidine"
        },
        {
          "id": 290745,
          "text": "Atropine"
        },
        {
          "id": 290746,
          "text": "Lignocaine"
        }
      ],
      "text": "Surinder Singh developed acute CHF and was put on digitalis therapy. ECG of this patient revealed the presence of ventricular extrasystoles. Which of the following drugs can be administered safely to this patient in order to counteract this arrhythmia?",
      "unique_key": "Q5307401",
      "question_audio": null,
      "question_video": null,
      "map_id": 34086115,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Lignocaine (Lidocaine). Digitalis toxicity can lead to ventricular arrhythmias, including ventricular extrasystoles (premature ventricular contractions - PVCs), ventricular tachycardia, and fibrillation, due to its action of inhibiting Na+/K+-ATPase, causing increased intracellular calcium and enhanced automaticity. Lidocaine, a Class IB antiarrhythmic, is the preferred drug for treating ventricular arrhythmias due to digitalis toxicity. It acts by blocking sodium channels, reducing excitability in ischemic and depolarized myocardial tissue, and suppressing ectopic ventricular foci without significantly affecting normal conduction. Moreover, lidocaine has a minimal effect on atrial tissue and AV conduction, making it safer in digitalis toxicity, as it does not exacerbate AV block. Incorrect Options: (A) Amiodarone – Incorrect Amiodarone is a Class III antiarrhythmic that prolongs the action potential duration and QT interval. While it is effective for ventricular arrhythmias, it is not the first choice in digitalis-induced arrhythmias because it can worsen bradyarrhythmias and increase the risk of QT prolongation, which may lead to torsades de pointes. (B) Quinidine – Incorrect Quinidine is a Class IA antiarrhythmic that blocks sodium channels and prolongs the QT interval. However, it is contraindicated in digitalis toxicity because it increases digoxin levels by displacing it from tissue-binding sites and inhibiting its renal clearance, worsening toxicity. It can also increase ventricular ectopic activity and promote more severe arrhythmias. (C) Atropine – Incorrect Atropine is a muscarinic antagonist used to increase heart rate in bradyarrhythmias. It does not suppress ventricular extrasystoles caused by digitalis toxicity. While it may be used in cases of digitalis-induced bradycardia or AV block, it is ineffective for treating ventricular arrhythmias and is not the correct choice here.",
      "correct_choice_id": 290746,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51436,
      "choices": [
        {
          "id": 290747,
          "text": "Hyperkalemia should be avoided to reduce the likelihood of procainamide toxicity"
        },
        {
          "id": 290748,
          "text": "A possible drug interaction with digoxin suggest that digoxin blood levels should be obtained before and after starting procainamide"
        },
        {
          "id": 290749,
          "text": "Procainamide cannot be used if the patient has asthma because it has a beta blocking effect"
        },
        {
          "id": 290750,
          "text": "Procainamide is not active by the oral route Hyperkalemia increases the toxicity of class la antiarrhythmics."
        }
      ],
      "text": "In deciding on a treatment for a 60 years old patient, Golu, who has chronic heart disease and rheumatoid arteritis, you wish to give him procainamide. He is already taking digoxin, hydrochlorothiazide and potassium supplementation. Which of the following is a relevant statement?",
      "unique_key": "Q3378878",
      "question_audio": null,
      "question_video": null,
      "map_id": 34681976,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Hyperkalemia should be avoided to reduce the likelihood of procainamide toxicity. Procainamide is a Class IA antiarrhythmic that works by blocking sodium channels and prolonging the action potential duration and refractory period. Like other Class I antiarrhythmics, its effects are potentiated by hyperkalemia. Elevated potassium levels can increase myocardial excitability and slow conduction, thereby enhancing the proarrhythmic effects of procainamide, increasing the risk of torsades de pointes and ventricular arrhythmias. Since the patient is already taking potassium supplementation and hydrochlorothiazide (which can alter potassium balance), careful monitoring of potassium levels is essential to prevent procainamide toxicity. Incorrect Options: (B) A possible drug interaction with digoxin suggests that digoxin blood levels should be obtained before and after starting procainamide While procainamide and digoxin are both used for arrhythmias, they do not have a significant direct pharmacokinetic interaction. Unlike quinidine, which increases digoxin levels by reducing its renal clearance, procainamide does not significantly alter digoxin metabolism or clearance. Therefore, routine digoxin level monitoring before and after starting procainamide is not necessary, though general monitoring is always advisable in cardiac patients. (C) Procainamide cannot be used if the patient has asthma because it has a beta-blocking effect Procainamide does not have beta-blocking properties. It is a sodium channel blocker and has no significant effect on β-receptors or bronchoconstriction. Beta-blockers like propranolol or metoprolol are the ones contraindicated in asthma due to their potential to cause bronchospasm. Therefore, procainamide is not contraindicated in asthma patients. (D) Procainamide is not active by the oral route Procainamide can be administered orally, though its bioavailability is lower than when given intravenously. It has an active metabolite (N-acetylprocainamide, NAPA), which contributes to its antiarrhythmic effects. While IV procainamide is preferred for acute arrhythmias, the oral form is effective for long-term management, making this statement incorrect.",
      "correct_choice_id": 290747,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51437,
      "choices": [
        {
          "id": 290751,
          "text": "Sublingual"
        },
        {
          "id": 290752,
          "text": "Slow intravenous infusion"
        },
        {
          "id": 290753,
          "text": "Intravenous bolus injection"
        },
        {
          "id": 290754,
          "text": "Oral"
        }
      ],
      "text": "A patient of acute myocardial infarction being treated in intensive care unit developed left ventricular failure with raised central venous pressure. It was decided to use nitroglycerine. which route of administration would be most suitable?",
      "unique_key": "Q4221038",
      "question_audio": null,
      "question_video": null,
      "map_id": 34310503,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Slow intravenous infusion. In a patient with acute myocardial infarction (MI) complicated by left ventricular failure (LVF) and raised central venous pressure (CVP), nitroglycerine (NTG) is used to reduce preload and afterload, improving cardiac function. The slow intravenous (IV) infusion is the most suitable route because: Precise titration of dose – IV infusion allows gradual adjustment of nitroglycerine levels based on hemodynamic response, minimizing risks of hypotension and reflex tachycardia. Rapid onset of action – IV infusion provides immediate vasodilation, which is essential in acute settings like left ventricular failure. Sustained therapeutic effect – Unlike sublingual or bolus forms, continuous IV infusion maintains stable blood levels, ensuring a prolonged and controlled vasodilatory effect. Explanation of Incorrect Options: (A) Sublingual – Incorrect Sublingual nitroglycerine is used for rapid relief of angina but is not ideal for continuous hemodynamic control in acute LVF. It has a short duration of action, and repeated dosing may cause wide fluctuations in blood pressure, increasing the risk of hypotension and reflex tachycardia. (C) Intravenous bolus injection – Incorrect A single IV bolus of nitroglycerine is not recommended because it can cause sudden and excessive vasodilation, leading to severe hypotension and worsening myocardial perfusion. A controlled infusion is preferred for gradual preload and afterload reduction. (D) Oral – Incorrect Oral nitroglycerine undergoes extensive first-pass metabolism, leading to delayed and unpredictable effects. This makes it unsuitable for acute management of LVF and raised CVP in a critically ill patient.",
      "correct_choice_id": 290752,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51438,
      "choices": [
        {
          "id": 290755,
          "text": "Trimetazidine"
        },
        {
          "id": 290756,
          "text": "Ivabradine"
        },
        {
          "id": 290757,
          "text": "Sildenafil"
        },
        {
          "id": 290758,
          "text": "Ranolazine"
        }
      ],
      "text": "Which of the following acts by inhibiting late Na channels in myocardium",
      "unique_key": "Q7615727",
      "question_audio": null,
      "question_video": null,
      "map_id": 34357966,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Ranolazine. Ranolazine is an anti-anginal drug that acts by inhibiting late sodium (Na+) channels in the myocardium. During ischemia, there is an increase in late Na+ current, which leads to intracellular calcium overload via the Na+/Ca2+ exchanger. This increases myocardial wall tension and oxygen demand, worsening ischemia. By blocking late Na+ channels, ranolazine reduces intracellular Na+ and indirectly decreases calcium overload, thereby improving myocardial relaxation and reducing ischemic damage without affecting heart rate or blood pressure. Incorrect Options: (A) Trimetazidine – Incorrect Trimetazidine is a metabolic modulator that works by shifting myocardial metabolism from fatty acid oxidation to glucose oxidation, making oxygen utilization more efficient. It does not act on Na+ channels. (B) Ivabradine – Incorrect Ivabradine selectively inhibits the funny current (I_f) in the sinoatrial (SA) node, leading to a reduction in heart rate without affecting myocardial contractility or conduction. It does not block Na+ channels. (C) Sildenafil – Incorrect Sildenafil is a phosphodiesterase-5 (PDE-5) inhibitor, used primarily for pulmonary hypertension and erectile dysfunction. It works by increasing cGMP levels, leading to vasodilation. It does not act on myocardial Na+ channels.",
      "correct_choice_id": 290758,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/50511321698478928/50511321698478928.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/50511321698478928/50511321698478928.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51439,
      "choices": [
        {
          "id": 290759,
          "text": "Left ventricular infraction is suspected"
        },
        {
          "id": 290760,
          "text": "Systolic BP is"
        },
        {
          "id": 290761,
          "text": "Heart rate is"
        },
        {
          "id": 290762,
          "text": "Patient has taken sildenafil in the past 24 hours"
        }
      ],
      "text": "GTN should not be administered in case of MI in the below conditions except",
      "unique_key": "Q9843064",
      "question_audio": null,
      "question_video": null,
      "map_id": 34752547,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) In the context of a myocardial infarction (MI), GTN is administered to alleviate chest pain and reduce the workload on the heart. It achieves this by dilating blood vessels, which lowers blood pressure and decreases the pressure the heart has to pump against (afterload) and the volume of blood returning to the heart (preload). When a left ventricular infarction is suspected, the heart muscle of the left ventricle is damaged. This can lead to a backup of blood, increasing pressure in the lungs and causing shortness of breath. By reducing the preload and afterload, GTN helps to reduce the heart's oxygen demand and can improve the flow of blood to the ischemic area, making it a beneficial treatment.",
      "correct_choice_id": 290759,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51440,
      "choices": [
        {
          "id": 290763,
          "text": "Voltage dependent K+ channel"
        },
        {
          "id": 290764,
          "text": "Receptor operated K+ channel"
        },
        {
          "id": 290765,
          "text": "Na+ activated K+ channel"
        },
        {
          "id": 290766,
          "text": "ATP sensitive K+ channel"
        }
      ],
      "text": "Nicorandil acts on",
      "unique_key": "Q2050600",
      "question_audio": null,
      "question_video": null,
      "map_id": 34559722,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Nicorandil is a potassium channel opener that primarily acts on ATP-sensitive K+ (K_ATP) channels, making option D the correct answer. It works by activating these channels, leading to hyperpolarization of vascular smooth muscle cells. This results in vasodilation, particularly in coronary arteries, reducing afterload and preload, and improving myocardial oxygen supply. Additionally, nicorandil has a nitrate-like effect, contributing to its anti-anginal properties by releasing nitric oxide, further enhancing vasodilation. Now, let’s evaluate why the other options are incorrect: Option A: Voltage-dependent K+ channel – These channels open or close in response to changes in membrane potential rather than ATP levels. Nicorandil does not primarily act through this mechanism, making this option incorrect. Option B: Receptor-operated K+ channel – These channels are regulated by ligand binding to specific receptors, such as G-protein-coupled receptors. Nicorandil does not require receptor activation for its action, ruling out this option. Option C: Na+-activated K+ channel – These channels are activated by intracellular sodium levels, which is not the mechanism of action of nicorandil. Thus, this option is also incorrect.",
      "correct_choice_id": 290766,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/9026561698479058/9026561698479058.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/9026561698479058/9026561698479058.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51441,
      "choices": [
        {
          "id": 290767,
          "text": "Nifedipine"
        },
        {
          "id": 290768,
          "text": "Nitrates"
        },
        {
          "id": 290769,
          "text": "Verapamil"
        },
        {
          "id": 290770,
          "text": "ACE inhibitors"
        }
      ],
      "text": "A patient is on propranolol for performance anxiety, which of the following drugs should not be given to this patient",
      "unique_key": "Q9989662",
      "question_audio": null,
      "question_video": null,
      "map_id": 34512079,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Verapamil. Verapamil is a non-dihydropyridine calcium channel blocker (CCB) that primarily acts on the heart by reducing heart rate and contractility. Since propranolol is a non-selective beta-blocker that also decreases heart rate and contractility, the combination of these two drugs can lead to severe bradycardia, atrioventricular (AV) block, and even heart failure due to excessive negative chronotropic and inotropic effects. This combination should be avoided, especially in patients with underlying conduction abnormalities or compromised cardiac function. Explanation for incorrect options: Option A: Nifedipine – Nifedipine is a dihydropyridine calcium channel blocker that primarily acts on vascular smooth muscle, causing vasodilation and reducing blood pressure. Unlike verapamil, it does not significantly affect heart rate or cardiac conduction, making it relatively safe to use with propranolol. However, caution is needed to avoid excessive hypotension. Option B: Nitrates – Nitrates, such as nitroglycerin, are potent vasodilators that primarily reduce preload and myocardial oxygen demand. When combined with propranolol, they may cause excessive hypotension, but they do not have direct effects on cardiac conduction. Therefore, while caution is advised, nitrates can still be used with careful monitoring. Option D: ACE inhibitors – ACE inhibitors (e.g., enalapril, lisinopril) reduce blood pressure by inhibiting the renin-angiotensin-aldosterone system (RAAS). They do not have significant effects on heart rate or cardiac conduction, making them generally safe to use with propranolol. In fact, ACE inhibitors are often combined with beta-blockers in conditions like heart failure and hypertension.",
      "correct_choice_id": 290769,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/37621701698479115/37621701698479115.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/37621701698479115/37621701698479115.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51442,
      "choices": [
        {
          "id": 290771,
          "text": "Metoprolol"
        },
        {
          "id": 290772,
          "text": "Bisoprolol"
        },
        {
          "id": 290773,
          "text": "Carvedilol"
        },
        {
          "id": 290774,
          "text": "Nadolol"
        }
      ],
      "text": "Which of the following beta blocker is not used in Chronic CHF",
      "unique_key": "Q7290232",
      "question_audio": null,
      "question_video": null,
      "map_id": 34420523,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Nadolol. Nadolol is a non-selective beta blocker that is generally not used in the management of chronic heart failure (CHF). While beta blockers are commonly used to improve outcomes in CHF patients, nadolol is not recommended because it has a long half-life and does not have the specific cardioselectivity required for the effective treatment of CHF. Other beta blockers like metoprolol, bisoprolol, and carvedilol have shown to improve survival rates and are routinely used in the treatment of CHF due to their beneficial effects on heart rate and cardiac remodeling. Explanation for incorrect options: Option A: Metoprolol – Metoprolol is a cardioselective beta-1 blocker, which is widely used in the treatment of chronic heart failure. It helps reduce heart rate, blood pressure, and myocardial workload, leading to improved survival rates in CHF patients. It is commonly used and well-established in CHF management. Option B: Bisoprolol – Bisoprolol is another cardioselective beta-1 blocker and is often used in the treatment of chronic heart failure. Like metoprolol, it has been shown to improve survival and reduce hospitalizations in patients with CHF by slowing the heart rate and reducing myocardial oxygen demand. Option C: Carvedilol – Carvedilol is a non-selective beta blocker with additional alpha-blocking properties. It has proven benefits in chronic heart failure because of its ability to reduce afterload (via alpha blockade) and lower heart rate (via beta blockade), making it an important drug in CHF management. It has been shown to improve survival rates and reduce hospitalizations in patients with CHF.",
      "correct_choice_id": 290774,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/51151651698479336/51151651698479336.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/51151651698479336/51151651698479336.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51443,
      "choices": [
        {
          "id": 290775,
          "text": "B blocker of choice in patients with peripheral artery disease"
        },
        {
          "id": 290776,
          "text": "Longer acting because of its accumulation in adipose tissues"
        },
        {
          "id": 290777,
          "text": "Ratio of a1- to B-antagonist potency for carvedilol is approximately 1:10"
        },
        {
          "id": 290778,
          "text": "Reduces mortality in patients with congestive failure"
        }
      ],
      "text": "Which of the following is incorrect about Carvedilol",
      "unique_key": "Q3054419",
      "question_audio": null,
      "question_video": null,
      "map_id": 34753673,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Longer acting because of its accumulation in adipose tissues. Carvedilol is a non-selective beta-blocker with additional alpha-1 blocking properties, making it effective in treating conditions like congestive heart failure (CHF) and hypertension. However, its prolonged action is not due to accumulation in adipose tissues. Instead, its long duration of action is related to its pharmacokinetic properties, including a relatively long half-life (about 7-10 hours). While it is lipophilic and can accumulate in tissues, its extended action is not solely attributed to adipose tissue accumulation, making this statement incorrect. Explanation for incorrect options: Option A: Beta-blocker of choice in patients with peripheral artery disease – Carvedilol is indeed considered an appropriate beta-blocker for patients with peripheral artery disease (PAD) because of its alpha-1 antagonism, which leads to vasodilation and reduced afterload. This can be beneficial in PAD, where vasodilation helps improve blood flow to the extremities, making this statement correct. Option C: Ratio of alpha-1 to beta-antagonist potency for carvedilol is approximately 1:10 – This is a correct statement. Carvedilol has a stronger beta-blocking effect than its alpha-1 blocking effect, with the ratio of alpha-1 to beta-antagonist potency being approximately 1:10. This ratio explains why carvedilol reduces blood pressure effectively (through beta-blockade and vasodilation from alpha-blockade). Option D: Reduces mortality in patients with congestive heart failure – This is also a correct statement. Carvedilol has been shown to reduce mortality and hospitalizations in patients with congestive heart failure (CHF). Its combined beta-blocking and alpha-1 blocking properties contribute to improving heart function, reducing afterload, and decreasing mortality in heart failure patients.",
      "correct_choice_id": 290776,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/62789721698479350/62789721698479350.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/62789721698479350/62789721698479350.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51444,
      "choices": [
        {
          "id": 290779,
          "text": "It is immunogenic"
        },
        {
          "id": 290780,
          "text": "Used for treating digoxin toxicity"
        },
        {
          "id": 290781,
          "text": "Given by IV infusion"
        },
        {
          "id": 290782,
          "text": "Digoxin-Digibind complex is rapidly excreted by kidney"
        }
      ],
      "text": "Which of the following is incorrect about DIGIBIND",
      "unique_key": "Q4895937",
      "question_audio": null,
      "question_video": null,
      "map_id": 34032864,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) It is immunogenic. DIGIBIND is not immunogenic. It is a digoxin-specific antibody (ovine-derived) that binds to digoxin, forming a complex that neutralizes its toxic effects. The goal is to remove digoxin from the bloodstream, preventing further toxicity. Although DIGIBIND is derived from sheep, it does not typically provoke significant immune responses in most patients when used in clinical settings. Therefore, its immunogenicity is not a significant concern. Explanation for incorrect options: Option B: Used for treating digoxin toxicity – This is correct. DIGIBIND is specifically used in the treatment of digoxin toxicity. It works by binding to digoxin in the bloodstream and neutralizing its effects, particularly in cases of severe toxicity or life-threatening arrhythmias. Option C: Given by IV infusion – This is also correct. DIGIBIND is administered via intravenous (IV) infusion. This allows for rapid distribution and action in cases of acute digoxin toxicity. Option D: Digoxin-Digibind complex is rapidly excreted by kidney – This is correct. Once DIGIBIND binds to digoxin, the complex is excreted by the kidneys. The complex is typically filtered by the renal system and excreted in the urine, helping to clear the digoxin from the body and reducing toxicity.",
      "correct_choice_id": 290779,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/74875941698479366/74875941698479366.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/74875941698479366/74875941698479366.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51445,
      "choices": [
        {
          "id": 290783,
          "text": "Renal impairment"
        },
        {
          "id": 290784,
          "text": "Hypercalcemia"
        },
        {
          "id": 290785,
          "text": "Hyperkalemia"
        },
        {
          "id": 290786,
          "text": "Hypomagnesemia"
        }
      ],
      "text": "Digoxin toxicity is increased by all except",
      "unique_key": "Q1384446",
      "question_audio": null,
      "question_video": null,
      "map_id": 34302413,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Hyperkalemia. Hyperkalemia actually decreases the risk of digoxin toxicity rather than increasing it. This is because high potassium levels can reduce the binding of digoxin to its receptor, the Na+/K+ ATPase pump, making digoxin less effective and lowering its toxicity. Therefore, hyperkalemia is not a factor that increases digoxin toxicity. Explanation for incorrect options: Option A: Renal impairment – Renal impairment is a major risk factor for increased digoxin toxicity. Digoxin is primarily excreted by the kidneys, and in the case of renal dysfunction, the drug's elimination is slowed, leading to accumulation in the body. This can result in toxic levels of digoxin. Option B: Hypercalcemia – Hypercalcemia can also increase the risk of digoxin toxicity. Elevated calcium levels can enhance the effects of digoxin on the heart, especially its ability to increase intracellular calcium, which can exacerbate arrhythmias and other toxic effects. Option D: Hypomagnesemia – Hypomagnesemia (low magnesium levels) is another factor that can increase the risk of digoxin toxicity. Low magnesium can sensitize the heart to digoxin and contribute to arrhythmias, making toxicity more likely.",
      "correct_choice_id": 290785,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/3929021698479381/3929021698479381.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/3929021698479381/3929021698479381.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51446,
      "choices": [
        {
          "id": 290787,
          "text": "6 hrs"
        },
        {
          "id": 290788,
          "text": "8hrs"
        },
        {
          "id": 290789,
          "text": "24hrs"
        },
        {
          "id": 290790,
          "text": "12hrs"
        }
      ],
      "text": "Digoxin undergoes relatively slow distribution to effector site(s), so in order to achieve its antiarrhythmic effect, loading dose should be given with in",
      "unique_key": "Q5033046",
      "question_audio": null,
      "question_video": null,
      "map_id": 34747435,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) 24hrs. Digoxin undergoes relatively slow distribution to its effector sites, particularly the heart, because it has a narrow therapeutic window and a slow onset of action. To achieve its antiarrhythmic effect, a loading dose is typically administered over a period of 24 hours to reach therapeutic levels and maintain adequate drug concentrations in the body. This extended distribution time helps ensure effective therapeutic levels without overloading the system. Explanation for incorrect options: Option A: 6 hrs – A 6-hour timeframe is too short for digoxin's slow distribution to its effector sites. Given its pharmacokinetics, digoxin typically requires a longer time for steady-state concentrations to be reached and for its effects to become apparent. Option B: 8 hrs – While 8 hours may allow some distribution, it is still shorter than the typical time needed to achieve therapeutic effects for digoxin in most patients. The 24-hour window is more in line with the slow distribution process and the time required for a therapeutic effect. Option D: 12 hrs – 12 hours is still not sufficient to achieve optimal digoxin levels for an effective antiarrhythmic action. Given that the drug has a half-life of about 36 hours, it is important to provide a loading dose over a 24-hour period to allow adequate accumulation at the effector site.",
      "correct_choice_id": 290789,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51447,
      "choices": [
        {
          "id": 290791,
          "text": "Better cardiac stimulation"
        },
        {
          "id": 290792,
          "text": "Less peripheral Vasoconstriction"
        },
        {
          "id": 290793,
          "text": "Lower risk of cardiac arrhythmias"
        },
        {
          "id": 290794,
          "text": "More CNS stimulation"
        }
      ],
      "text": "Dobutamine is preferred over dopamine in cardiogenic shock because of its effect related to",
      "unique_key": "Q1335764",
      "question_audio": null,
      "question_video": null,
      "map_id": 34651737,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Less peripheral Vasoconstriction. Dobutamine is preferred over dopamine in cardiogenic shock because it primarily stimulates β1 receptors in the heart, leading to increased cardiac contractility and output with less peripheral vasoconstriction. This is an important advantage because dopamine at higher doses can cause significant vasoconstriction due to its α1 receptor stimulation, which may worsen afterload and increase the heart’s workload. Dobutamine does not have this vasoconstrictive effect and provides better hemodynamic stability with minimal increased vascular resistance. Explanation for incorrect options: Option A: Better cardiac stimulation – While dobutamine does provide better cardiac stimulation by acting on β1 receptors, this is not the main reason it is preferred over dopamine in cardiogenic shock. Both drugs enhance cardiac output, but dopamine may cause additional problems with vasoconstriction at higher doses. Option C: Lower risk of cardiac arrhythmias – Dobutamine and dopamine both carry a risk of arrhythmias, particularly in the setting of high doses. However, dopamine is associated with a higher risk of arrhythmias due to its β1 receptor activation, which leads to increased afterload. While dobutamine is less arrhythmogenic than dopamine in some cases, the main advantage is its minimal vasoconstriction. Option D: More CNS stimulation – Neither dobutamine nor dopamine has significant CNS stimulation effects, as both are primarily acting on the cardiovascular system. The choice of dobutamine over dopamine is not related to CNS stimulation but to its more favorable cardiovascular effects.",
      "correct_choice_id": 290792,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51448,
      "choices": [
        {
          "id": 290795,
          "text": "Gynaecomastia"
        },
        {
          "id": 290796,
          "text": "Dryness of Mouth"
        },
        {
          "id": 290797,
          "text": "Tremors"
        },
        {
          "id": 290798,
          "text": "Diminution in Psychic energy"
        }
      ],
      "text": "Following adverse effects are seen with methyldopa except",
      "unique_key": "Q7875619",
      "question_audio": null,
      "question_video": null,
      "map_id": 34705648,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Tremors. Methyldopa is an alpha-2 adrenergic agonist that is commonly used as an antihypertensive agent, especially during pregnancy. It primarily works by decreasing sympathetic outflow, thereby reducing blood pressure. While it has several known side effects, tremors are not typically associated with methyldopa use. The other side effects listed are more commonly seen with this medication. Explanation for incorrect options: Option A: Gynaecomastia – Gynaecomastia (the enlargement of breast tissue in males) is a well-known side effect of methyldopa. It occurs due to its action on prolactin levels and the modulation of hormonal balances. This side effect is due to the increase in prolactin secretion caused by methyldopa, making it a recognized adverse effect. Option B: Dryness of Mouth – Dry mouth (xerostomia) is a common side effect of methyldopa and other alpha-2 agonists. It is due to the anticholinergic effects of methyldopa, leading to reduced saliva production. This is one of the more frequent adverse effects associated with methyldopa therapy. Option D: Diminution in Psychic Energy – A diminution in psychic energy, which includes feelings of lethargy, depression, or mental fatigue, is another common side effect of methyldopa. This occurs due to its central nervous system (CNS) effects, as it acts centrally to reduce sympathetic nervous system activity.",
      "correct_choice_id": 290797,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51449,
      "choices": [
        {
          "id": 290799,
          "text": "Gingival hyperplasia"
        },
        {
          "id": 290800,
          "text": "Confusion"
        },
        {
          "id": 290801,
          "text": "Blurred vision"
        },
        {
          "id": 290802,
          "text": "Nausea and vomiting"
        }
      ],
      "text": "All of the following can be a side effect of digitalis toxicity except:",
      "unique_key": "Q5435775",
      "question_audio": null,
      "question_video": null,
      "map_id": 34512468,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Gingival hyperplasia Explanation: Gingival hyperplasia is not a known side effect of digitalis toxicity. Digitalis (digoxin) primarily affects the cardiac, gastrointestinal, and neurological systems, but gingival hyperplasia is typically associated with other medications, such as phenytoin (antiepileptic) or calcium channel blockers. Therefore, option (A) is the correct answer. Explanation for Incorrect Options: (B) Confusion – Confusion is a common neurological symptom seen in digitalis toxicity. Other cognitive disturbances, such as delirium or disorientation, may also occur, especially in elderly patients. (C) Blurred vision – Blurred vision, or yellow-green halos, is a well-known visual disturbance associated with digitalis toxicity. It results from the drug’s effect on the retina and is one of the classic signs of overdose. (D) Nausea and vomiting – Nausea and vomiting are gastrointestinal symptoms frequently observed in digitalis toxicity. They occur due to the drug's direct irritant effect on the gastrointestinal tract and can also result from central nervous system involvement.",
      "correct_choice_id": 290799,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/48042211698479842/48042211698479842.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/48042211698479842/48042211698479842.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51450,
      "choices": [
        {
          "id": 290803,
          "text": "Beta-blockers"
        },
        {
          "id": 290804,
          "text": "B vitamin supplements"
        },
        {
          "id": 290805,
          "text": "Aspirin"
        },
        {
          "id": 290806,
          "text": "ACE inhibitors"
        }
      ],
      "text": "You are called to admit a 32-year-old male who presented to the emergency department with complaints of chest pain. He is admitted to a monitored floor and, during the course of hospitalization, he is shown to have experienced a myocardial infarction. A homocysteine level is found to be very high. Which of the following is not routinely included in the treatment of an acute MI in this young patient?",
      "unique_key": "Q3427787",
      "question_audio": null,
      "question_video": null,
      "map_id": 34976442,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) B vitamin supplements Explanation: In the context of an acute myocardial infarction (MI), B vitamin supplements are not routinely included in the treatment. Elevated homocysteine levels are a potential risk factor for cardiovascular disease, but there is no conclusive evidence that routine B vitamin supplementation (such as folic acid, B6, or B12) reduces the risk of adverse events following an MI, including mortality or recurrent infarctions. While B vitamins may lower homocysteine levels, this does not appear to translate into improved clinical outcomes for MI patients. Explanation for Incorrect Options: (A) Beta-blockers: Beta-blockers are routinely used in the treatment of acute MI, especially in young patients. They help to reduce the heart rate, blood pressure, and myocardial oxygen demand, which can limit the extent of myocardial damage. Additionally, beta-blockers have been shown to improve survival and reduce the risk of recurrent infarctions in patients after an MI. They also help prevent arrhythmias, which can be common in the acute phase following an MI. (C) Aspirin: Aspirin is a cornerstone of therapy for acute MI and is routinely used to prevent thrombus formation by inhibiting platelet aggregation. This is crucial in the acute setting of an MI, where thrombus formation in a coronary artery leads to vessel occlusion and infarction. Aspirin reduces the risk of further cardiovascular events and improves outcomes for patients with acute MI. (D) ACE inhibitors: ACE inhibitors (angiotensin-converting enzyme inhibitors) are commonly used in the management of acute MI, particularly in patients with left ventricular dysfunction or heart failure. They help by reducing the preload and afterload, decreasing myocardial oxygen demand, and preventing remodeling of the left ventricle, which can lead to heart failure. ACE inhibitors have been shown to improve survival rates after an MI.",
      "correct_choice_id": 290804,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51451,
      "choices": [
        {
          "id": 290807,
          "text": "Digoxin"
        },
        {
          "id": 290808,
          "text": "Warfarin"
        },
        {
          "id": 290809,
          "text": "Low dose subcutaneous heparin"
        },
        {
          "id": 290810,
          "text": "Aspirin"
        }
      ],
      "text": "A patient Amit Kumar is suffering from atherosclerosis. Which of the following is the most beneficial drug for prevention of stroke in this patient?",
      "unique_key": "Q5479321",
      "question_audio": null,
      "question_video": null,
      "map_id": 34978254,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Aspirin. Aspirin is the most beneficial drug for preventing stroke in patients with atherosclerosis. It works by inhibiting platelet aggregation, which is a key factor in the formation of thrombi that can lead to stroke, particularly in patients with atherosclerotic disease. Aspirin is widely used for its antiplatelet effects in patients with risk factors for stroke, such as atherosclerosis. Now, let's review the incorrect options: A. Digoxin: Digoxin is primarily used to treat atrial fibrillation and heart failure by increasing the force of heart contractions and controlling heart rate. It does not have a role in stroke prevention for patients with atherosclerosis. B. Warfarin: Warfarin is an anticoagulant used for stroke prevention in certain conditions like atrial fibrillation, but it is not typically used in patients with atherosclerosis unless they also have a condition that predisposes them to blood clots, such as atrial fibrillation. C. Low dose subcutaneous heparin: Heparin is an anticoagulant used in hospital settings for the prevention of deep vein thrombosis (DVT) or pulmonary embolism, but it is not indicated for stroke prevention in patients with atherosclerosis unless they have additional risk factors like venous thromboembolism.",
      "correct_choice_id": 290810,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/8632741698479932/8632741698479932.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/8632741698479932/8632741698479932.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51452,
      "choices": [
        {
          "id": 290811,
          "text": "Antiplatelet drugs"
        },
        {
          "id": 290812,
          "text": "Thrombolytics"
        },
        {
          "id": 290813,
          "text": "Plasminogen activator inhibitors"
        },
        {
          "id": 290814,
          "text": "Alteplase"
        }
      ],
      "text": "Drugs used in acute myocardial infarction are all EXCEPT",
      "unique_key": "Q9618349",
      "question_audio": null,
      "question_video": null,
      "map_id": 34582165,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Plasminogen activator inhibitors. Plasminogen activator inhibitors are not used in the treatment of acute myocardial infarction (AMI). In fact, they would be counterproductive in this context. These inhibitors block the conversion of plasminogen to plasmin, which is the enzyme responsible for breaking down fibrin in blood clots. In AMI, the goal is to dissolve the blood clot obstructing the coronary artery, so the use of plasminogen activator inhibitors would hinder clot breakdown and worsen the situation. Incorrect options: A. Antiplatelet drugs: Antiplatelet drugs, such as aspirin or P2Y12 inhibitors (e.g., clopidogrel, ticagrelor), are commonly used in the acute phase of a myocardial infarction. These drugs prevent platelet aggregation, which helps in reducing the formation of new clots and prevents further occlusion of the coronary arteries. B. Thrombolytics: Thrombolytic drugs, like alteplase, are used to break down the clot causing the heart attack. These drugs activate plasminogen to plasmin, which dissolves fibrin in the clot, restoring blood flow to the heart muscle. Thrombolytics are often used when percutaneous coronary intervention (PCI) is not immediately available. D. Alteplase: Alteplase is a thrombolytic drug that is frequently used in the management of acute myocardial infarction, particularly when PCI is not feasible within the recommended time window. It helps dissolve the clot and reestablish blood flow to the affected heart muscle.",
      "correct_choice_id": 290813,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/3780981698479984/3780981698479984.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/3780981698479984/3780981698479984.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51453,
      "choices": [
        {
          "id": 290815,
          "text": "Enalapril is contraindicated"
        },
        {
          "id": 290816,
          "text": "Furosemide will relieve the symptom but no effect on overall mortality"
        },
        {
          "id": 290817,
          "text": "Digoxin is useful if atrial arrhythmias are present"
        },
        {
          "id": 290818,
          "text": "Eplerenone is useful"
        }
      ],
      "text": "A 60 yr old patient with history of MI on irregular treatment, comes with a history of dyspnoea on exertion, occasional PND and edema. On examination, BP is 130/80, Mitral regurgitation is present, X Ray shows cardiomegaly, Echo has EF 35% and Serum Creatinine is 1.3. All of the following are true for treatment of this patient except?",
      "unique_key": "Q4270574",
      "question_audio": null,
      "question_video": null,
      "map_id": 34193187,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Enalapril is contraindicated. Enalapril is not contraindicated in this patient. In fact, ACE inhibitors such as enalapril are beneficial in heart failure with reduced ejection fraction (HFrEF), especially in patients with mitral regurgitation and dyspnea on exertion. They help in reducing afterload, preventing further myocardial remodeling, and improving symptoms in heart failure. The presence of a serum creatinine of 1.3 mg/dL suggests mild renal dysfunction, but enalapril can still be used with careful monitoring of kidney function and electrolytes. Enalapril is not contraindicated, but its dose may need to be adjusted based on the renal function. Explanation of Incorrect Options: (B) Furosemide will relieve the symptom but no effect on overall mortality – Correct. Furosemide, a loop diuretic, is used in heart failure to reduce symptoms such as edema and dyspnea by eliminating excess fluid. However, while furosemide provides symptomatic relief, it does not improve overall mortality in heart failure. It addresses the congestion but does not modify the disease progression. (C) Digoxin is useful if atrial arrhythmias are present – Correct. Digoxin is useful in patients with atrial fibrillation or atrial flutter, especially when rate control is required. It has a role in improving symptoms and controlling the ventricular rate in patients with heart failure and concomitant atrial arrhythmias. However, digoxin should be used cautiously, and renal function should be monitored, as it can be toxic in patients with renal dysfunction. (D) Eplerenone is useful – Correct. Eplerenone is an aldosterone antagonist that has been shown to improve survival in patients with heart failure with reduced ejection fraction (HFrEF). It helps in reducing fluid retention and preventing fibrosis, which is particularly important in patients with heart failure. It is beneficial in this patient and is recommended in patients with reduced ejection fraction and symptoms of heart failure, provided there are no contraindications such as severe renal dysfunction or hyperkalemia.",
      "correct_choice_id": 290815,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/78221391700304780/78221391700304780.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/78221391700304780/78221391700304780.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51454,
      "choices": [
        {
          "id": 290819,
          "text": "Acetaminophen"
        },
        {
          "id": 290820,
          "text": "Aminocaproic acid"
        },
        {
          "id": 290821,
          "text": "Clopidogrel"
        },
        {
          "id": 290822,
          "text": "Dipyridamole"
        }
      ],
      "text": "A 64-yrs-old woman has had several episodes of transient ischemic attacks (TIAs). Aspirin would be a preferred treatment, but she has a history of severe “aspirin sensitivity” manifests as intense bronchoconstriction. What would be a best suitable alternative to the aspirin?",
      "unique_key": "Q1017947",
      "question_audio": null,
      "question_video": null,
      "map_id": 34123093,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Clopidogrel. Clopidogrel is an antiplatelet medication that works by inhibiting the ADP receptor on platelets, which prevents platelet aggregation. It is often used as an alternative to aspirin for patients who cannot tolerate aspirin due to aspirin sensitivity or other contraindications. In this case, the 64-year-old woman has a history of bronchoconstriction (a form of aspirin sensitivity), which makes aspirin unsuitable for her. Clopidogrel is a good alternative because it does not induce the same bronchospasm or respiratory issues associated with aspirin. It has been shown to be effective in preventing transient ischemic attacks (TIAs) and stroke in patients with a history of vascular events, making it an appropriate choice for this patient. Explanation of Incorrect Options: (A) Acetaminophen – Incorrect. Acetaminophen is an analgesic and antipyretic drug, but it does not have antiplatelet properties. It is useful for pain relief and fever reduction, but it does not reduce the risk of thrombotic events such as TIAs or strokes. Since this patient requires an antiplatelet therapy for her TIA prevention, acetaminophen would not be suitable as a substitute for aspirin. (B) Aminocaproic acid – Incorrect. Aminocaproic acid is an antifibrinolytic agent that inhibits the breakdown of fibrin and helps to prevent excessive bleeding. It is typically used in conditions where bleeding is a concern, such as in surgeries or certain bleeding disorders, rather than in the prevention of TIA or stroke. Since this patient is at risk of ischemic events, aminocaproic acid would not help with thrombotic prevention and is not suitable in this scenario. (D) Dipyridamole – Incorrect. Dipyridamole is an antiplatelet drug that works by inhibiting phosphodiesterase and increasing cyclic AMP levels in platelets, thereby inhibiting platelet aggregation. It is used for stroke prevention in some cases, often in combination with aspirin. However, dipyridamole can cause headaches and gastrointestinal discomfort, and it is generally less effective as a monotherapy for stroke prevention compared to clopidogrel. Additionally, it is not as commonly used alone when an alternative to aspirin is needed.",
      "correct_choice_id": 290821,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/63921921700305265/63921921700305265.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/63921921700305265/63921921700305265.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51455,
      "choices": [
        {
          "id": 290823,
          "text": "Exercise program involving alternating running and walking on a daily basis"
        },
        {
          "id": 290824,
          "text": "Increase in dietary intake of sodium to 2,000 mg/d"
        },
        {
          "id": 290825,
          "text": "Stopping use of nonsteroidal anti-inflammatory agents"
        },
        {
          "id": 290826,
          "text": "Use of b-blockers at high doses"
        }
      ],
      "text": "A 67-year-old chronic smoker with COPD and chronic heart failure presents to his primary care physician for follow-up. The patient takes multiple medications for these problems. Which of the following strategies may prove to have additional benefit in the treatment of this patient?",
      "unique_key": "Q8981198",
      "question_audio": null,
      "question_video": null,
      "map_id": 34199056,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Stopping use of nonsteroidal anti-inflammatory agents (NSAIDs). NSAIDs, such as ibuprofen and naproxen, can worsen both chronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF). Effect on CHF: NSAIDs inhibit cyclooxygenase (COX), reducing prostaglandin synthesis. This leads to: Sodium and water retention, worsening fluid overload and edema in CHF. Increased systemic vascular resistance, making it harder for the heart to pump blood effectively. Increased risk of acute kidney injury, further impairing fluid balance. Effect on COPD: NSAIDs increase the risk of gastrointestinal bleeding, which is already higher in COPD patients due to frequent corticosteroid use. Additionally, some NSAIDs may cause bronchospasm, worsening respiratory symptoms in susceptible patients. Explanation of Incorrect Options: (A) Exercise program involving alternating running and walking on a daily basis While exercise is beneficial for both CHF and COPD, a high-intensity program that includes running may be too strenuous for this patient. COPD patients often have limited exercise tolerance due to dyspnea. Instead, pulmonary rehabilitation involving low-intensity aerobic exercise and strength training is recommended. (B) Increase in dietary intake of sodium to 2,000 mg/d Heart failure patients should restrict sodium intake, as excess sodium leads to fluid retention, worsening pulmonary congestion, peripheral edema, and hypertension. The recommended daily sodium intake for CHF patients is <1,500 mg/day. Increasing sodium intake would be harmful, not beneficial. (D) Use of beta-blockers at high doses beta-blockers (e.g., metoprolol, bisoprolol, carvedilol) are beneficial in CHF by reducing myocardial oxygen demand and improving survival. However, high doses can worsen symptoms of COPD by causing bronchoconstriction. Instead, low-to-moderate doses of cardioselective beta-blockers (such as bisoprolol or metoprolol succinate) are preferred for CHF patients with COPD.",
      "correct_choice_id": 290825,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51456,
      "choices": [
        {
          "id": 290827,
          "text": "Activates antithrombin III"
        },
        {
          "id": 290828,
          "text": "Activates plasminogen"
        },
        {
          "id": 290829,
          "text": "Activates thrombin"
        },
        {
          "id": 290830,
          "text": "Blocks production of thromboxane A2"
        }
      ],
      "text": "A 45-year-old man with a family history of hyperlipidemia and heart disease comes to the ER diaphoretic with chest pain radiating to his left arm. An ECG shows ST segment elevation in leads II, III, and aVF. The doctor administers alteplase intravenously. How does alteplase work?",
      "unique_key": "Q7783575",
      "question_audio": null,
      "question_video": null,
      "map_id": 34541854,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Activates plasminogen. Alteplase is a tissue plasminogen activator (tPA) that converts plasminogen into plasmin, an enzyme responsible for breaking down fibrin clots. It is used for acute ST-elevation myocardial infarction (STEMI), ischemic stroke, and pulmonary embolism to rapidly dissolve thrombi and restore blood flow. Why is Alteplase Effective in This Case? The patient presents with ST-elevation myocardial infarction (STEMI) in leads II, III, and aVF, which suggests a right coronary artery occlusion. Rapid reperfusion is necessary to restore blood supply to the heart and prevent infarction. Thrombolytics like alteplase help dissolve the clot and improve outcomes in STEMI patients, particularly if percutaneous coronary intervention (PCI) is unavailable. Plasmin degrades fibrin clots, leading to thrombus dissolution and revascularization of the affected coronary artery. Explanation of Incorrect Options: (A) Activates antithrombin III: Antithrombin III inhibits thrombin (Factor IIa) and Factor Xa, reducing clot formation. This is the mechanism of action of heparin and low-molecular-weight heparins (LMWHs) like enoxaparin. Does not directly break down existing clots, making it ineffective for thrombolysis. (C) Activates thrombin: Thrombin (Factor IIa) is responsible for converting fibrinogen into fibrin, promoting clot formation. Alteplase does the opposite—it breaks down clots, rather than forming them. Thrombin activation would worsen the thrombus instead of resolving it. (D) Blocks production of thromboxane A2: Thromboxane A2 (TXA2) promotes platelet aggregation and vasoconstriction. Aspirin works by inhibiting cyclooxygenase (COX-1), thereby reducing TXA2 production and preventing platelet aggregation. Aspirin prevents new clots but does not dissolve existing thrombi, unlike alteplase.",
      "correct_choice_id": 290828,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/43619121700305618/43619121700305618.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/43619121700305618/43619121700305618.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51457,
      "choices": [
        {
          "id": 290831,
          "text": "Antibiotics"
        },
        {
          "id": 290832,
          "text": "β-Blockers"
        },
        {
          "id": 290833,
          "text": "Diuretics"
        },
        {
          "id": 290834,
          "text": "Inhibitors of the renin-angiotensin system"
        }
      ],
      "text": "A 61-year-old woman who is a long-term smoker presents to the emergency department with dyspnea and feeling faint. Physical examination reveals bilateral jugular venous distension and significant peripheral edema of both legs up to the knees. Treatment of this condition will be unaffected by which of the following classes of medications?",
      "unique_key": "Q5647465",
      "question_audio": null,
      "question_video": null,
      "map_id": 34067365,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Antibiotics. The patient is a long-term smoker presenting with dyspnea, jugular venous distension (JVD), and significant peripheral edema, which are signs of right-sided heart failure (cor pulmonale). This condition is often caused by chronic lung disease (e.g., COPD, pulmonary hypertension) leading to right ventricular dysfunction. The treatment for cor pulmonale focuses on reducing right ventricular overload, improving cardiac function, and addressing underlying lung disease. Commonly used medications include diuretics, β-blockers, and renin-angiotensin system (RAS) inhibitors, which help manage fluid retention, blood pressure, and cardiac workload. However, antibiotics do not play a role in treating cor pulmonale unless there is an associated infection like pneumonia or COPD exacerbation. Incorrect Options: (B) β-Blockers: β-Blockers (e.g., metoprolol, carvedilol) help manage heart failure and reduce cardiac workload. In left-sided heart failure, they improve ventricular function and survival, but their role in right-sided heart failure is less clear. However, selective β-blockers may still be used cautiously in patients with pulmonary hypertension to manage symptoms. (C) Diuretics: Diuretics (e.g., furosemide, spironolactone) are essential in treating fluid overload in right-sided heart failure. They help reduce peripheral edema and JVD by decreasing excess fluid retention. (D) Inhibitors of the Renin-Angiotensin System (RAS inhibitors): ACE inhibitors (e.g., enalapril, lisinopril) and ARBs (e.g., losartan, valsartan) help reduce afterload and improve heart function. Though their role in right-sided heart failure is not as strong as in left-sided heart failure, they may still be beneficial in managing systemic hypertension and reducing cardiac strain.",
      "correct_choice_id": 290831,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/24563611700305668/24563611700305668.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/24563611700305668/24563611700305668.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51458,
      "choices": [
        {
          "id": 290835,
          "text": "Dilated cardiac chambers"
        },
        {
          "id": 290836,
          "text": "Heart appears small"
        },
        {
          "id": 290837,
          "text": "Heart appears smooth"
        },
        {
          "id": 290838,
          "text": "Increased ability to eject blood"
        }
      ],
      "text": "A 73-year-old man with long-standing heart failure managed with digoxin and a b-blocker suddenly collapses in a while walking in a garden. Attempts to revive him are unsuccessful. Autopsy is performed. Which of the following changes in his heart would be expected to be noted?",
      "unique_key": "Q9774077",
      "question_audio": null,
      "question_video": null,
      "map_id": 34892362,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Dilated cardiac chambers. The patient had long-standing heart failure and was on digoxin and a β-blocker, which suggests he had systolic heart failure (heart failure with reduced ejection fraction, HFrEF). In systolic heart failure, the heart loses its ability to contract effectively, leading to chronic volume overload and progressive ventricular dilation. At autopsy, dilated cardiac chambers (particularly the left ventricle and left atrium) are a hallmark of this condition. Over time, myocyte hypertrophy and fibrosis occur due to chronic stress on the heart. The dilated ventricles have increased end-diastolic volume, leading to reduced ejection fraction and eventual heart failure. Patients with dilated cardiomyopathy (DCM) are at high risk for sudden cardiac death (SCD) due to arrhythmias, which likely explains the patient’s sudden collapse. Incorrect Options: (B) Heart appears small: In chronic heart failure with reduced ejection fraction (HFrEF), the heart does not appear small. Instead, the heart undergoes dilation and hypertrophy as a compensatory response to chronic volume overload. A small heart may be seen in conditions like restrictive cardiomyopathy, but not in dilated heart failure. (C) Heart appears smooth: In heart failure, the endocardium often shows fibrosis, scarring, or thrombi due to prolonged stress and remodeling. A smooth heart appearance is not characteristic of long-standing heart failure. (D) Increased ability to eject blood: In systolic heart failure (HFrEF), the heart’s ability to pump blood is reduced, leading to a low ejection fraction (EF <40%). If the heart had increased ability to eject blood, it would indicate preserved ejection fraction (HFpEF), hyperdynamic states, or compensatory mechanisms—none of which match this patient’s condition.",
      "correct_choice_id": 290835,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/23666711700305694/23666711700305694.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/23666711700305694/23666711700305694.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51459,
      "choices": [
        {
          "id": 290839,
          "text": "Blocks the activity of angiotensin II at its receptor"
        },
        {
          "id": 290840,
          "text": "Reduces preload"
        },
        {
          "id": 290841,
          "text": "Increases cardiac inotropy"
        },
        {
          "id": 290842,
          "text": "Inhibits production of angiotensin II"
        }
      ],
      "text": "A 60-year-old woman suffers an anterior wall myocardial infarction. She recovers well initially but soon develops left heart failure. Her physician prescribes multiple medications to treat different aspects of heart failure, including isosorbide dinitrate. What is the mechanism of action of this agent?",
      "unique_key": "Q7421279",
      "question_audio": null,
      "question_video": null,
      "map_id": 34889559,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Reduces preload. Isosorbide dinitrate is a nitrate that works by releasing nitric oxide (NO), which leads to vasodilation, primarily in the veins. This venodilation reduces venous return (preload), decreasing the amount of blood entering the left ventricle before contraction. By lowering preload, the left ventricular filling pressure is decreased, reducing myocardial oxygen demand and alleviating symptoms of heart failure, such as pulmonary congestion and dyspnea. In patients with left heart failure after a myocardial infarction (MI), reducing preload is beneficial because it helps to decrease pulmonary congestion and improve symptoms of volume overload (such as shortness of breath and edema). Explanation of Incorrect Options: (A) Blocks the activity of angiotensin II at its receptor Angiotensin II receptor blockers (ARBs), such as losartan or valsartan, work by blocking angiotensin II at the AT1 receptor, leading to vasodilation and reduced afterload. However, isosorbide dinitrate does not block angiotensin II receptors; instead, it acts as a nitric oxide donor to promote venodilation. This mechanism is distinct from that of ARBs, making this option incorrect. (C) Increases cardiac inotropy Inotropes, such as digoxin or dobutamine, increase cardiac contractility by enhancing calcium availability in cardiac muscle cells. Isosorbide dinitrate does not have inotropic effects; instead, it reduces preload to ease the heart’s workload. This makes (C) an incorrect choice. (D) Inhibits production of angiotensin II Angiotensin-converting enzyme (ACE) inhibitors, such as enalapril and lisinopril, reduce afterload and preload by blocking the conversion of angiotensin I to angiotensin II. Isosorbide dinitrate does not inhibit angiotensin II production, so this option is incorrect.",
      "correct_choice_id": 290840,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/4290251700305708/4290251700305708.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/4290251700305708/4290251700305708.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51460,
      "choices": [
        {
          "id": 290843,
          "text": "Increase in heart rate"
        },
        {
          "id": 290844,
          "text": "Decrease in sympathetic tone"
        },
        {
          "id": 290845,
          "text": "Increase in vagal tone"
        },
        {
          "id": 290846,
          "text": "Blockade of beta receptors"
        }
      ],
      "text": "A 70-year-old patient with atrial fibrillation is prescribed digoxin. What is the primary mechanism by which digoxin affects the autonomic nervous system?",
      "unique_key": "Q8910525",
      "question_audio": null,
      "question_video": null,
      "map_id": 34597187,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Increase in vagal tone. Digoxin exerts its primary autonomic effect by enhancing vagal (parasympathetic) tone, which leads to a decrease in heart rate and slowed conduction through the atrioventricular (AV) node. This vagomimetic effect is particularly useful in conditions like atrial fibrillation, where controlling the ventricular rate is crucial. By increasing vagal activity, digoxin prolongs the refractory period of the AV node, reducing the number of atrial impulses that reach the ventricles, thus slowing down the ventricular response. This mechanism makes digoxin effective for rate control in atrial fibrillation, especially in patients with heart failure, where its positive inotropic effect (due to Na+/K+-ATPase inhibition) also provides additional benefits. Incorrect Options: (A) Increase in heart rate Digoxin does not increase heart rate; rather, it reduces it by enhancing vagal tone and slowing AV nodal conduction. In fact, one of the key clinical uses of digoxin is to control heart rate in atrial fibrillation by decreasing excessive ventricular response. (B) Decrease in sympathetic tone While digoxin indirectly reduces sympathetic activity due to improved cardiac output and reduced compensatory adrenergic activation, its primary autonomic effect is vagal enhancement rather than direct sympathetic inhibition. The main impact on autonomic function is through increased parasympathetic (vagal) activity, which is why it slows AV nodal conduction. (D) Blockade of beta receptors Digoxin does not act as a beta-blocker. While both digoxin and beta-blockers can reduce heart rate, their mechanisms are different. Beta-blockers work by directly blocking beta-adrenergic receptors, whereas digoxin exerts its effect via vagal stimulation and AV nodal suppression. Additionally, beta-blockers lack the positive inotropic effect that digoxin provides, making digoxin more useful in atrial fibrillation with concurrent heart failure.",
      "correct_choice_id": 290845,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/54394441727533170/54394441727533170.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/54394441727533170/54394441727533170.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51461,
      "choices": [
        {
          "id": 290847,
          "text": "Digoxin"
        },
        {
          "id": 290848,
          "text": "Spironolactone"
        },
        {
          "id": 290849,
          "text": "Furosemide"
        },
        {
          "id": 290850,
          "text": "Metoprolol"
        }
      ],
      "text": "Which drug is commonly used as a first-line treatment for chronic heart failure?",
      "unique_key": "Q6660780",
      "question_audio": null,
      "question_video": null,
      "map_id": 34596583,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Metoprolol. Metoprolol, a β1-selective beta-blocker, is a first-line treatment for chronic heart failure with reduced ejection fraction (HFrEF). Beta-blockers like metoprolol, carvedilol, and bisoprolol have been proven to improve survival, reduce hospitalizations, and slow disease progression in heart failure. They work by reducing sympathetic activation, which helps prevent cardiac remodeling, decreases myocardial oxygen demand, and improves overall cardiac efficiency. Although beta-blockers initially reduce cardiac output, they provide long-term benefits by reducing heart rate, decreasing afterload, and preventing arrhythmias. Metoprolol is especially preferred due to its cardioselectivity, minimizing bronchospasm risk in patients with comorbid lung disease. Explanation of Incorrect Options: (A) Digoxin – Incorrect. Digoxin is not a first-line treatment for chronic heart failure. It is primarily used as an adjunct therapy in HFrEF with atrial fibrillation or in patients with persistent symptoms despite optimal guideline-directed medical therapy (GDMT). While digoxin enhances contractility (positive inotropy) by inhibiting Na+/K+-ATPase, it does not improve survival and is mainly used for symptomatic relief and heart rate control. (B) Spironolactone – Incorrect. Spironolactone, an aldosterone antagonist, is recommended in moderate to severe HFrEF (NYHA class III–IV), but it is not a first-line drug. It helps by reducing sodium retention, preventing myocardial fibrosis, and improving survival, particularly in patients with low ejection fraction and persistent symptoms despite ACE inhibitors and beta-blockers. However, it is used as an add-on therapy, not as an initial treatment. (C) Furosemide – Incorrect. Furosemide, a loop diuretic, is primarily used for symptomatic relief of fluid overload (pulmonary congestion, peripheral edema) in heart failure but does not modify disease progression or improve survival. It is useful in acute decompensations but is not a first-line drug for chronic heart failure. Instead, it is used as needed to manage congestion and volume overload while optimizing guideline-directed therapy.",
      "correct_choice_id": 290850,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/71158671727680955/71158671727680955.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/71158671727680955/71158671727680955.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51462,
      "choices": [
        {
          "id": 290851,
          "text": "Spironolactone"
        },
        {
          "id": 290852,
          "text": "Lisinopril"
        },
        {
          "id": 290853,
          "text": "Metoprolol"
        },
        {
          "id": 290854,
          "text": "Hydrochlorothiazide"
        }
      ],
      "text": "A 56-year-old man with a history of heart failure with reduced ejection fraction (HFrEF) and chronic kidney disease is on an ACE inhibitor, a beta-blocker, and a diuretic. He is now experiencing worsening renal function and hyperkalemia. Which of the following medications should be used with caution or potentially adjusted due to his renal function and potassium levels?",
      "unique_key": "Q5451266",
      "question_audio": null,
      "question_video": null,
      "map_id": 34501718,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Spironolactone. Spironolactone is a potassium-sparing diuretic that works by antagonizing aldosterone in the kidneys, which helps to prevent potassium loss while promoting sodium excretion. In patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF), spironolactone is commonly used to reduce fluid overload and improve cardiac outcomes. However, it can increase the risk of hyperkalemia, especially in patients with impaired renal function. Given that this patient already has worsening renal function and hyperkalemia, spironolactone should be used with caution, and its dosage may need to be adjusted or discontinued based on potassium levels and renal function. Explanation of Incorrect Options: (B) Lisinopril – Incorrect. Lisinopril is an ACE inhibitor that helps manage heart failure and hypertension by inhibiting the renin-angiotensin-aldosterone system (RAAS), leading to vasodilation and reduced blood pressure. While ACE inhibitors like lisinopril can also contribute to hyperkalemia, they are commonly used in patients with heart failure and renal dysfunction because they help prevent cardiac remodeling and protect kidney function. This patient is already on lisinopril, and although it should be monitored for hyperkalemia, the primary concern for hyperkalemia and worsening renal function is with spironolactone, not lisinopril. The ACE inhibitor may need dose adjustments or discontinuation if renal function deteriorates significantly, but it’s not the primary culprit in this case. (C) Metoprolol – Incorrect. Metoprolol is a beta-blocker commonly used to manage heart failure, hypertension, and arrhythmias by reducing heart rate and myocardial oxygen demand. Beta-blockers are generally well-tolerated in patients with chronic kidney disease and heart failure. Metoprolol does not have a significant impact on renal function or potassium levels, so it is less likely to be the cause of worsening renal function or hyperkalemia in this patient. However, careful monitoring is always recommended in patients with renal impairment. (D) Hydrochlorothiazide – Incorrect. Hydrochlorothiazide is a thiazide diuretic that is effective for managing hypertension and fluid retention. It works by promoting sodium and water excretion, and it typically does not cause hyperkalemia but may lead to hypokalemia instead. In patients with chronic kidney disease, thiazide diuretics are often used, but they are usually ineffective in advanced kidney disease (when GFR is significantly reduced). In this case, hydrochlorothiazide is unlikely to be the cause of hyperkalemia, and it does not require the same level of caution in terms of potassium levels as spironolactone does.",
      "correct_choice_id": 290851,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/52930701727681275/52930701727681275.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/52930701727681275/52930701727681275.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51463,
      "choices": [
        {
          "id": 290855,
          "text": "Angiotensin II receptor blockers (ARBs)"
        },
        {
          "id": 290856,
          "text": "Calcium channel blockers"
        },
        {
          "id": 290857,
          "text": "Thiazide diuretics"
        },
        {
          "id": 290858,
          "text": "ACE inhibitors"
        }
      ],
      "text": "A 55-year-old man with a history of ischemic heart disease is started on a new antihypertensive medication. He reports experiencing severe headaches and flushing. Which class of antihypertensive drugs is most likely responsible for these symptoms?",
      "unique_key": "Q6942516",
      "question_audio": null,
      "question_video": null,
      "map_id": 34419921,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Calcium channel blockers. Calcium channel blockers (CCBs), particularly dihydropyridine CCBs (e.g., amlodipine), are known to cause headaches and flushing as common side effects. These symptoms are primarily due to vasodilation, which occurs as CCBs inhibit calcium ion entry into smooth muscle cells, leading to arterial dilation and reduced vascular resistance. This dilation can cause headaches (due to increased blood flow) and flushing (due to widened blood vessels). These side effects are more prominent with dihydropyridine CCBs, while non-dihydropyridine CCBs (e.g., verapamil, diltiazem) are less likely to cause these symptoms. Explanation of Incorrect Options: (A) Angiotensin II receptor blockers (ARBs) – Incorrect. ARBs (e.g., losartan, valsartan) are commonly used to treat hypertension and ischemic heart disease. They work by blocking the effects of angiotensin II, which causes vasodilation and reduces blood pressure. While ARBs may cause some side effects such as dizziness, hyperkalemia, or renal dysfunction, headaches and flushing are not typical side effects of this drug class. Therefore, ARBs are less likely to be responsible for the patient's symptoms in this case. (C) Thiazide diuretics – Incorrect. Thiazide diuretics (e.g., hydrochlorothiazide, chlorthalidone) work by promoting sodium and water excretion, reducing blood volume, and lowering blood pressure. Common side effects include electrolyte imbalances (e.g., hypokalemia, hyponatremia) and dehydration, but headaches and flushing are not commonly associated with thiazide diuretics. Therefore, thiazide diuretics are unlikely to be responsible for the symptoms described. (D) ACE inhibitors – Incorrect. ACE inhibitors (e.g., enalapril, lisinopril) are used to treat hypertension and ischemic heart disease by inhibiting the angiotensin-converting enzyme, leading to vasodilation and decreased blood pressure. While ACE inhibitors can cause side effects such as cough, angioedema, and hyperkalemia, headaches and flushing are not common side effects. These drugs are less likely to cause the symptoms described in this patient.",
      "correct_choice_id": 290856,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/76388631727681332/76388631727681332.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/76388631727681332/76388631727681332.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51464,
      "choices": [
        {
          "id": 290859,
          "text": "Ranolazine"
        },
        {
          "id": 290860,
          "text": "Sotalol"
        },
        {
          "id": 290861,
          "text": "Dofetilide"
        },
        {
          "id": 290862,
          "text": "Ivabradine"
        }
      ],
      "text": "A 60-year-old woman with a history of heart failure and atrial fibrillation is experiencing persistent symptoms despite being on optimal heart failure therapy. Which of the following medications could be considered for additional symptom relief and improved heart failure management?",
      "unique_key": "Q2602481",
      "question_audio": null,
      "question_video": null,
      "map_id": 34195945,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Ivabradine. Ivabradine is a If current inhibitor that reduces heart rate by inhibiting the funny current (I_f) in the sinoatrial node. It is specifically indicated for patients with heart failure with reduced ejection fraction (HFrEF) who have a heart rate of greater than 70 beats per minute despite being on beta-blocker therapy at the highest tolerated dose. Ivabradine helps improve heart failure symptoms by reducing heart rate, which in turn reduces myocardial oxygen demand and improves heart efficiency. In clinical trials, ivabradine has been shown to reduce hospitalizations for heart failure and improve quality of life in patients with HFrEF, making it an excellent addition for symptom relief and improved heart failure management in this patient. Explanation of Incorrect Options: (A) Ranolazine – Incorrect. Ranolazine is an anti-anginal medication primarily used to treat chronic angina. It works by inhibiting late sodium current, which reduces intracellular calcium overload and thus decreases myocardial oxygen consumption. While it can be used in ischemic heart disease and angina, ranolazine is not indicated for heart failure management and does not significantly affect heart failure symptoms. Therefore, it would not be appropriate for improving heart failure symptoms in this patient. (B) Sotalol – Incorrect. Sotalol is a beta-blocker with additional antiarrhythmic properties (class III). It is used to manage arrhythmias, particularly atrial fibrillation and ventricular arrhythmias. However, it is not typically used to treat heart failure symptoms directly, especially in patients who are already on optimal heart failure therapy. Sotalol has the potential to worsen heart failure symptoms in patients with reduced ejection fraction due to its negative inotropic effects. Therefore, it is not the best choice for this patient who requires symptom relief for heart failure. (C) Dofetilide – Incorrect. Dofetilide is a class III antiarrhythmic drug used for the conversion and maintenance of sinus rhythm in patients with atrial fibrillation. While it is effective in controlling arrhythmias, it does not have a direct impact on heart failure management and is typically used in patients with atrial fibrillation rather than those requiring additional heart failure therapy. Dofetilide can also increase the risk of torsades de pointes and would not be the optimal choice for managing heart failure symptoms in this patient.",
      "correct_choice_id": 290862,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/26572861727681365/26572861727681365.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/26572861727681365/26572861727681365.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51465,
      "choices": [
        {
          "id": 290863,
          "text": "Ranolazine"
        },
        {
          "id": 290864,
          "text": "Spironolactone"
        },
        {
          "id": 290865,
          "text": "Lisinopril"
        },
        {
          "id": 290866,
          "text": "Atorvastatin"
        }
      ],
      "text": "A 67-year-old man with a history of coronary artery disease and stable angina is evaluated for ongoing symptom management. His current medications include a beta-blocker and a calcium channel blocker. Which of the following additional medications might provide further symptom relief for his angina?",
      "unique_key": "Q9630281",
      "question_audio": null,
      "question_video": null,
      "map_id": 34883213,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Ranolazine. Ranolazine is a sodium channel inhibitor used in the treatment of chronic stable angina. It works by reducing intracellular calcium overload, which helps decrease myocardial oxygen demand without significantly affecting heart rate or blood pressure. This makes it an ideal medication to add to a regimen for angina management, particularly when symptoms are not adequately controlled with beta-blockers and calcium channel blockers. Ranolazine provides an additional mechanism of action to relieve angina symptoms, making it a good option for patients like this who have stable angina despite current therapy. Explanation of Incorrect Options: (B) Spironolactone – Incorrect. Spironolactone is an aldosterone antagonist primarily used in the management of heart failure, hypertension, and hyperaldosteronism. While it has beneficial effects in reducing mortality in patients with heart failure, it is not used for angina management. Spironolactone does not directly address the underlying mechanisms of angina and would not be expected to provide significant symptom relief in this patient. (C) Lisinopril – Incorrect. Lisinopril is an ACE inhibitor commonly used to manage hypertension, heart failure, and chronic kidney disease. While it is beneficial for reducing mortality in patients with coronary artery disease (CAD) and heart failure, it does not provide direct symptom relief for stable angina. Lisinopril is often used as part of the long-term management of CAD, but it would not be the primary choice for improving angina symptoms in this patient who is already on effective angina therapy (beta-blocker and calcium channel blocker). (D) Atorvastatin – Incorrect. Atorvastatin is a statin used to lower LDL cholesterol and reduce the risk of atherosclerotic cardiovascular events (such as heart attacks and strokes). While statins are an essential part of secondary prevention in patients with coronary artery disease, they do not directly relieve angina symptoms. Atorvastatin helps stabilize plaques and reduce the risk of future cardiovascular events, but it does not provide immediate symptom relief for angina. Thus, it is not a medication specifically used for improving angina control in this patient.",
      "correct_choice_id": 290863,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/72674081727681519/72674081727681519.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/72674081727681519/72674081727681519.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51466,
      "choices": [
        {
          "id": 290867,
          "text": "Spironolactone"
        },
        {
          "id": 290868,
          "text": "Eplerenone"
        },
        {
          "id": 290869,
          "text": "Angiotensin-converting enzyme (ACE) inhibitor"
        },
        {
          "id": 290870,
          "text": "Calcium channel blocker"
        }
      ],
      "text": "A 62-year-old man with a history of ischemic heart disease and recent myocardial infarction is being evaluated for secondary prevention. His current medications include a statin and an antiplatelet agent. Which of the following medications should be added to his regimen to further reduce the risk of cardiovascular events?",
      "unique_key": "Q7003851",
      "question_audio": null,
      "question_video": null,
      "map_id": 34234043,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Angiotensin-converting enzyme (ACE) inhibitor. ACE inhibitors, such as lisinopril, enalapril, and ramipril, are highly recommended for secondary prevention in patients with a history of ischemic heart disease (IHD) and myocardial infarction (MI). They provide multiple benefits, including reducing blood pressure, decreasing the risk of heart failure, reducing mortality, and preventing further cardiovascular events. ACE inhibitors work by inhibiting the conversion of angiotensin I to angiotensin II, leading to vasodilation, reduced afterload, and preload. These effects reduce the heart's workload and improve outcomes in patients post-MI, especially those with left ventricular dysfunction or heart failure. Explanation of Incorrect Options: (A) Spironolactone – Incorrect. Spironolactone is an aldosterone antagonist used primarily in heart failure and secondary hyperaldosteronism. While it can reduce mortality in patients with heart failure (particularly those with heart failure with reduced ejection fraction), it is not a routine addition for all patients post-MI unless they have significant heart failure or elevated aldosterone levels. Spironolactone is beneficial for preventing remodeling and reducing fibrosis but is not a first-line agent for all patients with ischemic heart disease or recent myocardial infarction. (B) Eplerenone – Incorrect. Eplerenone is also an aldosterone antagonist, similar to spironolactone, but with a more selective action on mineralocorticoid receptors, causing fewer side effects like gynecomastia. It is indicated in patients with heart failure or post-MI with left ventricular dysfunction and is beneficial in reducing hospitalizations and improving survival. However, like spironolactone, eplerenone is not added routinely for all post-MI patients but is considered in specific cases with heart failure or high-risk post-MI patients with significant left ventricular dysfunction. (D) Calcium channel blocker – Incorrect. Calcium channel blockers (CCBs), such as amlodipine and diltiazem, are typically used for hypertension, angina, and arrhythmias, but they are not first-line medications for secondary prevention post-MI. They may be used to manage symptoms like angina, but they do not have the same mortality-reducing benefits as ACE inhibitors. In fact, non-dihydropyridine CCBs (like verapamil or diltiazem) may be avoided post-MI in certain patients, especially if there is concern about bradycardia or heart block. Therefore, ACE inhibitors are a more appropriate choice for secondary prevention in this patient.",
      "correct_choice_id": 290869,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/66116311727682316/66116311727682316.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/66116311727682316/66116311727682316.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51467,
      "choices": [
        {
          "id": 290871,
          "text": "Thiazide diuretics"
        },
        {
          "id": 290872,
          "text": "Beta-blockers"
        },
        {
          "id": 290873,
          "text": "Angiotensin II receptor blockers (ARBs)"
        },
        {
          "id": 290874,
          "text": "Alpha-blockers"
        }
      ],
      "text": "A 55-year-old man with a history of coronary artery disease and diabetes is being considered for a new antihypertensive agent. He is particularly concerned about managing his hypertension without affecting his blood sugar levels. Which of the following medications would be a suitable choice that does not negatively impact glucose control?",
      "unique_key": "Q9611369",
      "question_audio": null,
      "question_video": null,
      "map_id": 34749561,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Angiotensin II receptor blockers (ARBs). Angiotensin II receptor blockers (ARBs), such as losartan and valsartan, are a class of antihypertensive medications that work by blocking the action of angiotensin II, leading to vasodilation and reduced blood pressure. ARBs are especially beneficial for patients with coronary artery disease and diabetes, as they have been shown to improve renal outcomes and reduce the risk of cardiovascular events. Importantly, ARBs do not negatively impact glucose metabolism, making them a suitable choice for patients with diabetes who need blood pressure control without worsening blood sugar levels. Explanation of Incorrect Options: (A) Thiazide diuretics – Incorrect. Thiazide diuretics (e.g., hydrochlorothiazide) are commonly used for hypertension but can have an adverse effect on glucose metabolism, especially with long-term use. They may lead to hyperglycemia and insulin resistance, which can worsen blood sugar control in diabetic patients. Therefore, thiazides may not be the best choice for a patient who is concerned about managing both hypertension and blood sugar levels. (B) Beta-blockers – Incorrect. Beta-blockers (e.g., metoprolol, atenolol) are commonly used in patients with coronary artery disease and hypertension, but they can also have negative effects on glucose metabolism. Beta-blockers can mask symptoms of hypoglycemia (such as tremors and tachycardia) and may lead to increased insulin resistance, potentially worsening blood sugar control in diabetic patients. Therefore, beta-blockers are generally not preferred for patients with diabetes who are concerned about their blood sugar levels. (D) Alpha-blockers – Incorrect. Alpha-blockers (e.g., doxazosin) are used for hypertension but are not considered first-line agents due to their side effect profile. They are not typically associated with any significant effect on glucose metabolism, but they may cause orthostatic hypotension (low blood pressure when standing up) and reflex tachycardia (increased heart rate), which can be problematic in some patients. While they don’t directly worsen glucose control, they are less commonly used compared to ARBs and are generally not the preferred choice for diabetic patients.",
      "correct_choice_id": 290873,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51468,
      "choices": [
        {
          "id": 290875,
          "text": "Digoxin"
        },
        {
          "id": 290876,
          "text": "Lisinopril"
        },
        {
          "id": 290877,
          "text": "Metoprolol"
        },
        {
          "id": 290878,
          "text": "Nifedipine"
        }
      ],
      "text": "A 75-year-old woman with a history of chronic heart failure and persistent atrial fibrillation is being evaluated for additional therapy. Which medication is most appropriate for controlling her heart rate and improving heart failure symptoms?",
      "unique_key": "Q2049977",
      "question_audio": null,
      "question_video": null,
      "map_id": 34348298,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Digoxin. Digoxin is a cardiac glycoside that has two primary effects beneficial in this patient: it helps control the heart rate in patients with atrial fibrillation and improves symptoms of heart failure. Digoxin works by inhibiting the Na+/K+-ATPase pump, which increases intracellular calcium in the heart, enhancing myocardial contractility and improving cardiac output. It also slows conduction through the atrioventricular (AV) node, which helps control ventricular rate in atrial fibrillation. Therefore, digoxin is an appropriate choice for a patient with chronic heart failure and persistent atrial fibrillation. Explanation of Incorrect Options: (B) Lisinopril – Incorrect. Lisinopril is an ACE inhibitor, commonly used in heart failure for angiotensin II blockade, reducing blood pressure and improving heart failure outcomes. While it’s beneficial for heart failure, it does not directly control the heart rate in atrial fibrillation. It could be part of a comprehensive heart failure treatment plan but is not the first choice specifically for rate control in atrial fibrillation. (C) Metoprolol – Incorrect. Metoprolol is a beta-blocker that also helps in controlling heart rate, particularly in atrial fibrillation. However, in a patient with chronic heart failure, beta-blockers like metoprolol are usually started once the patient's heart failure is stable, as they can initially worsen symptoms in an unstable heart failure patient. For a patient with more severe or persistent heart failure, digoxin might be more beneficial for immediate rate control and symptom relief. (D) Nifedipine – Incorrect. Nifedipine is a calcium channel blocker used to treat hypertension and angina, but it is not appropriate for rate control in atrial fibrillation in patients with heart failure. Nifedipine is a dihydropyridine calcium channel blocker, which acts primarily on vascular smooth muscle rather than the heart. It could potentially worsen heart failure by reducing vascular tone and preload, which could be harmful in heart failure patients. Therefore, it is not recommended for this patient’s condition.",
      "correct_choice_id": 290875,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/35964091727682424/35964091727682424.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/35964091727682424/35964091727682424.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 51469,
      "choices": [
        {
          "id": 290879,
          "text": "Hyperkalemia"
        },
        {
          "id": 290880,
          "text": "Hypocalcemia"
        },
        {
          "id": 290881,
          "text": "Digoxin toxicity"
        },
        {
          "id": 290882,
          "text": "Drug interaction"
        }
      ],
      "text": "A 65-year-old woman with heart failure with reduced ejection fraction (HFrEF) and chronic atrial fibrillation is managed on digoxin. She reports experiencing visual disturbances and nausea. What is the most likely cause of her symptoms?",
      "unique_key": "Q8314249",
      "question_audio": null,
      "question_video": null,
      "map_id": 34541011,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Digoxin toxicity. Digoxin toxicity is the most likely cause of the visual disturbances (such as yellow halos or blurred vision) and nausea. These symptoms are classic signs of digoxin toxicity, which can occur due to several factors such as renal impairment, drug interactions, or electrolyte imbalances (especially hypokalemia). In patients with heart failure with reduced ejection fraction (HFrEF) and atrial fibrillation, digoxin is commonly prescribed to help control the heart rate and improve myocardial contractility. However, the therapeutic window for digoxin is narrow, and toxicity can develop if plasma levels become too high, leading to gastrointestinal symptoms (nausea, vomiting) and visual disturbances. Explanation of Incorrect Options: (A) Hyperkalemia – Incorrect. Hyperkalemia typically presents with muscle weakness, arrhythmias, or ECG changes such as peaked T waves. Although hyperkalemia can occur in digoxin toxicity, it is more often associated with renal dysfunction, aldosterone antagonists, or potassium-sparing diuretics. In this case, the patient’s symptoms (visual disturbances and nausea) are more indicative of digoxin toxicity than hyperkalemia alone. (B) Hypocalcemia – Incorrect. Hypocalcemia can cause muscle cramps, tetany, and cardiac arrhythmias but is unlikely to cause visual disturbances and nausea in this context. While digoxin does affect calcium homeostasis by inhibiting the Na+/K+-ATPase pump, which indirectly increases intracellular calcium, hypocalcemia itself is not a typical cause of these particular symptoms. The patient's symptoms are more consistent with digoxin toxicity. (D) Drug interaction – Incorrect. Drug interactions can contribute to digoxin toxicity, especially if a medication affects digoxin metabolism (e.g., amiodarone or verapamil). While drug interactions can indeed increase digoxin levels, the specific symptoms of visual disturbances and nausea are more indicative of digoxin toxicity rather than a simple interaction alone. However, if there is a suspicion of a drug interaction, it could contribute to elevated digoxin levels, but the symptoms are still pointing towards toxicity itself.",
      "correct_choice_id": 290881,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/51252361727682441/51252361727682441.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/51252361727682441/51252361727682441.m3u8",
      "question_images": [],
      "explanation_images": []
    }
  ]
}